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ABSTRACT

The adverse effects of maternal smoking on infant mortality and morbidity has been
well documented in the literature. Maternal tobacco use is causally associated with fetal
growth restriction and correlates negatively with folate intake and metabolism. Studies have
examined the association between smoking and folate levels during pregnancy, but very few
have assessed this relationship using objective and accurate measures of both variables.
Furthermore, despite evidence of a causal association between smoking in pregnancy and
intrauterine growth restriction, and a plausible relationship between tobacco use and low
maternal folate which is required for optimal fetal growth, no experimental study has
investigated the potential benefit of folic acid in mitigating the adverse effects of maternal
smoking on fetal outcomes.
The objectives of this study were to investigate the relationship between maternal
smoking and folate levels and examine the efficacy of higher-strength folic acid
supplementation, in combination with enrollment in a smoking cessation program, in
promoting fetal body and brain growth. Our hypothesis was that women who smoke during
pregnancy have lower peri-conceptional folic acid reserves than non-smoker pregnant women
and that folic acid reserves will decrease with increasing cotinine level. Additionally, smoker
pregnant women on higher-strength folic acid (4mg daily) in combination with smoking
vi

cessation programs will experience faster fetal brain growth and have infants with larger body
size at birth compared to smokers on the standard dose of folic acid (0.8mg daily).
Participants were pregnant women (smokers and non-smokers) who received antenatal
care between 2010-2014 at the Genesis Clinic of Tampa, a community health center affiliated
with the Department of Obstetrics and Gynecology of the University of South Florida (USF).
They were aged 18-44 years and had a gestational age of less than 21 weeks at study
enrollment. To determine the peri-conceptional folic acid reserves in smoking versus nonsmoking women during pregnancy and associated sociodemographic factors, baseline (crosssectional) data from a double-blinded randomized controlled trial were analyzed using Tobit
regression models (n=496). Smoking information was assessed using salivary cotinine, a
sensitive and specific tobacco use biomarker. Folate reserve was measured using red blood cell
folate. To investigate the efficacy of higher-strength folic acid on fetal body and brain size,
baseline and follow-up data from pregnant smokers enrolled in the randomized controlled trial
were utilized (n=345). All primary analyses of the clinical trial data were conducted on a
modified intention-to-treat basis and included participants who completed the trial with an
observed endpoint, irrespective of compliance to protocol. Multilevel modeling, linear
regression, and log-binomial regression analyses were conducted.
A significant inverse association between salivary cotinine level and periconceptional
red blood cell folate concentration was found among pregnant women in the early to midpregnancy period. Smokers on high-dose folate during pregnancy had infants with a 140.38g
higher birth weight than infants of their counterparts on standard dose folate (P =0.047).
Mothers who received higher strength folate had a 31.0% lower risk of having babies with SGA
vii

compared to their mothers on the standard-dose (adjusted relative risk-ARR=0.69, 95% CI:
0.46–1.03; (P =0.073)). High-dose folate had no significant effect on the intrauterine rate of
growth in head circumference, and head circumference and brain weight at birth in our trial
sample. However, the brain-body ratio of infants of mothers who received high-dose treatment
was 0.33 percentage-point lower than that for infants of mothers who received the standard
dose of folate (P =0.044).
Higher strength folic acid supplementation in pregnant women who smoke might be a
cost-effective and safe option to improve birth outcomes and reduce low birth weight and SGA
associated infant morbidity and mortality. Future studies with larger sample sizes and diverse
populations are indicated to confirm or refute the results of this study. Randomized controlled
trials starting during the preconception period and with follow-up until delivery are warranted,
to identify the most folate-sensitive period of fetal growth and determine the optimal dose of
folic acid supplement. Further research investigating several pathways through which the
effects of prenatal smoking on adverse birth outcomes can be mitigated is needed.
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CHAPTER ONE:

INTRODUCTION

The adverse effects of maternal tobacco smoking on fetal development have been well
documented. Smoking during pregnancy is associated with increased risks for a reduction in
fetal body and brain size,1-4 indices that are associated with future adverse health outcomes
and increased mortality. There is overwhelming evidence of a causal association between
smoking in pregnancy and intrauterine growth restriction,1-3,5 and a plausible relationship
between smoking and low maternal folate6-8 which is required for optimal fetal growth. Despite
these well-established relationships, no experimental study has investigated the benefit of folic
acid supplementation in reducing the adverse effects of maternal smoking on fetal outcomes.

STUDY RATIONALE
Despite the known risk of higher mortality and morbidity rates among infants born to
smoking mothers, approximately 12% of women continue to smoke during pregnancy.3
Maternal smoking is causally associated with fetal growth restriction.1-4 Smoking also has a
negative impact on folate metabolism, and diet quality including folate intake.9-10 Adequate
folate intake, particularly in pregnancy is required for cell division, and deficiency of this
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essential micronutrient has been associated with adverse birth outcomes such as preterm birth
and congenital abnormalities.8,11,12
Several studies have examined the association between smoking and folate level in
pregnancy13-16 but very few have assessed this association using objective and specific measures
of both smoking and folate.17 Most of the previous studies utilized self-reports to distinguish
smokers and nonsmokers.13-15 Recently, Prasodjo and colleagues17 examined the relationship
between tobacco smoke exposure and whole blood folate concentrations in pregnant women
from Cincinnati, Ohio. The investigators could not calculate RBC folate, which would have
allowed for direct comparability with folate status of women from prior studies. In addition,
folate was measured using samples that had been stored for 4-6 years so folate may have
degraded due to storage length. To demonstrate a valid association between the smoking in
pregnancy and folate, it is important that both the exposure and outcome variables are directly
and accurately measured. This current study attempted to fill this gap in the literature. With the
use of baseline data from a randomized controlled trial, we assessed the periconceptional folic
acid reserves in smoking and non-smoking women, and factors associated with
periconceptional folate levels during pregnancy. Smoking information was based on a sensitive
and specific tobacco smoke biomarker. Furthermore, folate level was measured using red blood
cell folate (also called erythrocyte folate), which is a better indicator of long-term folate storage
than serum folate.18-19
The association between maternal smoking during pregnancy and fetal body size has
been investigated in several cross-sectional and longitudinal studies.4,20,21 These studies found
that continued smoking during pregnancy leads to intrauterine growth restriction and reduced
2

growth of fetal head circumference and biparietal diameter which are parameters of total
growth restriction in fetuses.4,20-22 In the Generation R European study, Bakker and colleagues23
found that folic acid supplements might reduce some of the adverse effects of maternal
smoking on fetal growth and neonatal outcomes. These investigators conducted an
observational, prospective and population-based cohort study collecting information on
smoking and folic acid supplement use during pregnancy by use of questionnaires.23 Limitations
of this self-reported measure of exposures include underreporting of smoking status because
low correlations exist between cotinine concentrations and self-reported smoking status,24 over
reporting of use of folic acid supplements and subsequent misclassification of these variables.
The researchers concluded that the results from their observational study should be considered
hypothesis-generating and be confirmed using randomized controlled trials. 23 This current
study built on the findings in the Bakker et al23 study.
With the use of primary data from a double-blinded randomized controlled trial, and
validated biomarkers of folate and tobacco exposure, we tested the hypothesis of reduced
adverse effects of maternal smoking on fetal growth by specifically examining the effects of
higher strength folic acid supplementation on fetal brain and body size. To the best of our
knowledge, this randomized clinical trial is the first to investigate the efficacy of folic acid in
combination with smoking cessation programs in preventing adverse birth outcomes in smoking
mothers during pregnancy.
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SPECIFIC AIMS
The goal of this research was to understand the relationships between folate and fetal
development among smoking mothers and identify factors that may promote fetal growth and
development among mothers who smoke during pregnancy. The objective of the study was to
determine the factors associated with periconceptional folic acid reserve and investigate the
efficacy of folic acid in combination with smoking cessation in enhancing fetal brain growth and
body size among smoking mothers. The specific aims of this research were:
1. To examine the periconceptional folic acid reserves among smoking vs. non-smoking
women during pregnancy and associated sociodemographic factors.
2. To determine whether higher-strength folic acid in combination with enrollment in
smoking cessation programs will prevent a reduction in fetal body size among smokers
in pregnancy.
3. To determine the effect of higher-strength folic acid in combination with enrollment in
smoking cessation programs on fetal brain growth and development among women
who smoked during pregnancy.
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CHAPTER TWO:

MANUSCRIPT 1: MATERNAL COTININE LEVELS AND RED BLOOD CELL BLOOD FOLATE
CONCENTRATIONS IN THE PERICONCEPTIONAL PERIOD

ABSTRACT
Studies have examined the association between tobacco use and folate levels in
pregnancy, yet very few have assessed this relationship using objective and accurate measures
of both smoking and folate. In this study, the periconceptional folic acid reserves in smoking
and non-smoking women were evaluated, along with factors associated with periconceptional
folate levels during pregnancy. Smoking information, based on salivary cotinine, a highly
sensitive and specific tobacco smoke exposure biomarker was utilized. Furthermore, folate was
assessed using red blood cell (RBC) folate, which is a superior indicator of long-term folate
storage compared to serum folate. Participants were pregnant women who received antenatal
care between 2010-2015 at the Genesis Clinic of Tampa, a community health center affiliated
with the Department of Obstetrics and Gynecology of the University of South Florida (USF). A
total of 496 women were enrolled in the study.
Associations between smoking status/maternal salivary cotinine concentrations,
sociodemographic factors and folate concentrations were investigated using Tobit regression
analyses. Non-smokers had nearly 20 ng/mL higher mean concentration of RBC folate than
5

smokers, but the difference was not statistically significant (p-value= 0.4213). In contrast,
salivary cotinine levels were significantly associated with decreased erythrocyte blood folate
concentrations. For every one level increase in cotinine, folate levels reduced by 11.43 ng/mL
(p-value=0.032). Maternal body mass index, gestational age, stress, and depression were also
associated with folate levels.
Given the role of folic acid in fetal development, the identification of a modifiable risk factor
associated with low folate concentrations, such as smoking, may offer opportunities to prevent
adverse fetal outcomes. Thus, higher strength folic acid supplementation in smokers,
particularly in those who smoke frequently, might be beneficial in improving maternal RBC
folate concentrations and preventing adverse birth outcomes linked with tobacco exposure.

INTRODUCTION
Adequate folate intake during pregnancy is required for proper cell division, fetal
growth and development.25-26 Folate deficiency has been associated with health problems in
both mothers (such as anemia, peripheral neuropathy) and infants (such as preterm birth and
congenital abnormalities).26,27 The negative association between smoking in pregnancy and folic
acid intake and metabolism is well documented.6,13,17,28-30 Tobacco smoke exposure during
pregnancy may increase disease risk among children by reducing folate bioavailability during
the critical period of fetal development.13,14,16, 31,32 Despite substantial evidence of the
deleterious health effects of smoking, periconceptional smoking is prevalent. About 25.4% of
women in the United States smoke in the three months preceding pregnancy, and
approximately 15.0% of women smoke during the last trimester of gestation.33,34 Additionally,
6

about one-third of women of reproductive age who are at risk of becoming pregnant are also
exposed to environmental tobacco smoke i.e. second-hand exposure.35 Public health initiatives
have helped reduce the prevalence of smoking in pregnancy over the past few decades but
smoking remains relatively common among subgroups of these population such as women of
lower socioeconomic status.5
Studies have examined the association between tobacco use and folate level in
pregnancy,13-16 yet very few have assessed this relationship using objective and accurate
measures of both smoking and folate.17 Most previous studies utilized self-reports to
distinguish smokers and nonsmokers, while also including women with second-hand smoking
exposure as nonsmokers.13-15 Only two previous studies employed validated biomarkers of both
folate and smoking. 16-17 Pagan K et al16 measured smoking using serum thiocyanate, which is
not a specific biomarker. Numerous factors other than tobacco smoke exposure affect serum
thiocyanate, and these include exposure to cyanides and thiocyanate producing foods, such as
cabbage, garlic, and almonds.36 Prasodjo et al17 assessed folate using whole blood folate that
had been stored for approximately 6 years. Folate degradation was likely in their sample. To
demonstrate a valid association between smoking in pregnancy and folate level, it is important
that both the exposure and outcome variables are directly and accurately measured. This study
proposes to fill the literature gap in this regard, and would lead to better understanding of
prenatal factors that may contribute to adverse birth outcomes.
The periconceptional folic acid reserves in smoking and non-smoking women were
assessed, along with factors associated with periconceptional folate levels during pregnancy.
Smoking information, based on a highly sensitive and specific tobacco smoke biomarker, was
7

utilized. Furthermore, folate was assessed using red blood cell folate (erythrocyte folate), which
is a superior indicator of long-term folate storage compared to serum folate.18, 19

METHODS

Participants
This study used baseline data collected from smoking pregnant women who were enrolled in a
randomized clinical trial on the efficacy of high-dose folate in improving birth outcomes. We
also collected cross-sectional data from non-smoking pregnant women recruited to compare
their periconceptional folate reserve with the smokers’. Participants were pregnant women
who received antenatal care between 2010-2015 at the Genesis Clinic of Tampa, a community
health center affiliated with the Department of Obstetrics and Gynecology of the University of
South Florida (USF). Women who receive health care from this center are usually of low
socioeconomic status and mostly uninsured or are covered by Medicaid or emergency Medicaid
for pregnancy.
Flyers advertising the research study were posted around the clinic and distributed with
new patient intake forms. The intake clerk or study staff assessed each woman’s level of
interest. Written permission was obtained from interested women who were less than 21
weeks pregnant, based on a calculation from the first day of their last menstrual period (LMP).
Study personnel screened for eligibility which was defined as age 18-44 years, less than 21
weeks gestation at enrollment as confirmed by LMP and residency in Tampa, Florida, or
surrounding areas. Participants were excluded if there was evidence of an indication for
8

chronic blood transfusion and treatment with anti-convulsant medication. Women receiving
chronic blood transfusion may have inaccurate measures of folate RBC levels due to transfused
red blood cells (RBC). Patients treated with anticonvulsants can have folic acid deficiency as a
side effect of the medication.37 Written informed consent, which was available in both English
and Spanish was obtained from all the participating women. A total of 496 women were
enrolled in the study.
Following informed consent and before data collection, all participants had vaginal
ultrasonography to confirm the viability of the fetus and establish gestational age. Study
questionnaires and laboratory assessments of salivary cotinine and erythrocyte folate were
then completed. The study was funded by the James and Esther King Biomedical Research
Program, Florida Department of Health (grant numbers 4KB03 and 1KG14-33987), and was
registered at ClinicalTrials.gov (Identifier: NCT01248260). The trial protocol was approved by
the Institutional Review Board of the University of South Florida.

Outcome Assessment
Periconceptional folic acid reserve was measured by assessing maternal erythrocyte
folate concentration at study baseline (less than 21 weeks GA) using enzyme-linked
immunosorbent assay (ELISA). RBC folate was the preferred folate biomarker because it has
good correlation with serum folate and has advantages of long-term stability and reduced
susceptibility to sudden changes in diet (Galloway, 2013). Laboratory analysis was conducted at
Quest Diagnostics using EDTA blood. At this laboratory, the standard reference range for RBC
folate is 280 ng/mL to 1000 ng/ml. Folate levels greater than 1000 ng/ml were reported as
9

>1000ng/ml. However, for the purpose of data analysis, we truncated the >1000ng/ml values
(n=58) to 1000 ng/mL, 38 and defined folate level as a continuous variable.

Exposure Assessment
Periconceptional maternal smoking was measured through the use of a rapid semiquantitative screening test called NicAlert (Jant Pharmacal Corporation, Encino, CA). Maternal
saliva was tested for the presence of cotinine, a biological marker for nicotine. Salivary cotinine
analysis is the most sensitive and specific of the three types of cotinine measures. 39 This
method has a sensitivity of 99% and specificity of 82%.39 The cotinine test strip displays seven
levels (0-6), each of which represents a range of salivary cotinine concentrations. Higher levels
on the strip indicate higher range of cotinine. Based on the manufacturer’s guidelines,
individuals with reading at level 0 (cotinine concentration <10 ng/mL) are considered nonusers
of tobacco products while participants with at least a level 1 result are considered smokers.
Individuals with a cotinine level of 1 are either light active smokers or passive smokers.
Participants in this study were classified as smokers (active and passive) and non-smokers
based on this guideline. Maternal smoking was also treated as a continuous explanatory
variable in our analysis (cotinine level).

Potential Confounders
Based on prior knowledge, a number of maternal characteristics were considered as
potential confounding factors due to their demonstrated association with folate levels and
smoking. 6,17,33,40,41 These include sociodemographic factors (such as maternal age, race, marital
10

status, and insurance status), and perinatal factors such maternal body mass index (BMI)),
depression, stress, and gestational age. Smoking is strongly associated with psychological
factors such as depression and stress.42,43
Race/ethnicity was categorized into three groups: non-Hispanic black (black), nonHispanic white (white), and other (includes Hispanic). Age was defined as both continuous and
categorical variable (grouped as 18-14, 25-34 and ≥35 years). Marital status was dichotomized
as either married or unmarried, the latter included divorced, separated and unknown marital
status. Insurance (health insurance) was categorized as private or public/uninsured. BMI was
calculated using maternal self-reported pre-pregnancy weight and height measured at
enrollment. BMI was calculated as weight (kg)/ height (m)2 and categorized into normal
(<25·0kg/m2), overweight (25·0–29·9kg/m2) and obese (≥30·0kg/m2). Although 5 women had
BMI below 18.5 (underweight), they were included in the normal BMI group due to limited
sample. Gestational age was based on ultrasound fetal dating at study enrollment. Depression
was assessed using the Edinburgh Postnatal Depression Scale (EPSD). This is a validated tool for
assessing ante-natal and post-natal depressive symptoms.44 Mothers who score above 12 or 13
on the scale are likely to be suffering from depression.45 We dichotomized this variable as high
and low, using a cut-off point of 12. Stress was measured using the Perceived Stress Scale (PSS14) scale, which is a validated tool for comparisons between people in study samples.46 As a
result, women who had a score equal to or greater than the mean stress score for the sample
were classified as having high-stress levels, while those who had a score below the mean were
classified as having low-stress levels.
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Statistical Analyses
The projected sample size required to evaluate differences in periconceptional folic acid
reserves in women during pregnancy was 106 (53 smokers and non-smokers respectively). This
estimation was based on the following assumptions: (1) type 1 error rate of 5%; (2) 80% power
(3) minimal odds ratio of 1.2 for folate values reported among non-smoking vs. smoking
pregnant women; and (4) a standard deviation of 7.6 and 8.9 for smoking and non-smoking
mothers respectively.10,11,15,47 In this study, data was available on 496 women, suggesting
adequate power to detect a difference in periconceptional folic acid reserves among smoking
vs. non-smoking women if it exists.
Frequencies and percentages were used to describe the categorical maternal
sociodemographic and health-related characteristics of the study population by smoking status.
Chi-square tests of independence were used to test for differences in proportions. Means and
standard deviations were calculated for selected continuous variables. Spearman correlation
coefficient was used to assess the relationships between the continuous covariates, cotinine
level and erythrocyte folate. The outcome of interest, folate level was plotted using histogram,
and the distribution was assessed for normality. The plot suggests non-normal distribution
which could be explained by the laboratory’s folate reporting practices described earlier. As
shown in the Figure 2.1, if folate levels were not right-censored, the distribution of folate
concentration could have been approximately normal.
Due to the observed distribution of folate, parametric and nonparametric bivariate
analyses were conducted. Mean/standard deviation and median/interquartile range (IQR)
blood folate concentrations were calculated by socio-demographic and lifestyle characteristics.
12

Analysis of variance was used to examine if there were significant differences in the mean folic
acid reserves by selected characteristics of participants. The differences in the median folic acid
reserves by study participants’ characteristics were tested using Kruskal-Wallis test. It is a
nonparametric hypothesis test for comparing two or more independent samples, and is very
sensitive to differences in both location and shape of the empirical distribution functions of the
samples.48
Additionally, the associations between the study exposures (smoking status & maternal
salivary cotinine concentrations), sociodemographic and lifestyle factors and folate
concentrations were investigated using Tobit regression. This modeling method, which is also
known as censored regression, is the appropriate method for estimating linear relationships
between variables when the dependent variable is right-censored.49,50 The relationship
between the exposure variables and folate were examined in separate models. In the
regression models, we controlled for variables identified as potential confounders from prior
studies or from our analyses (variables associated with either cotinine or folate levels).
Stepwise regression modeling was utilized and model fit was examined based on AIC. Using the
variables in the adjusted model, we assessed for multicollinearity and found that depression
score and stress score were fairly strongly correlated (r=0.66). Thus, an interaction term was
introduced between these variables. Adjusted mean differences in folate levels were estimated
and reported from the models with the best fit. All hypothesis tests were two-tailed with a type
1 error rate fixed at 5%. SAS version 9.4 (SAS Institute, Cary, NC) was used to perform all
statistical analyses.
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RESULTS
A total of 496 pregnant women participated in the study; 345 smokers (69.6%) and 151
non-smokers (30.4%). The mean age and gestational age of the participants at enrollment were
27.0 years (SD±5.76) and 12.15 weeks (SD±3.85) respectively. Table 2.1 shows the baseline
characteristics of the study sample by maternal smoking status. Majority were aged 25-34 years
(49.5%), unmarried (82.5%), had public/no insurance (93.2%), obese (42.0%), and enrolled in
the study during the first trimester of pregnancy (57.9%). Significant differences in smoking
status were observed by race, marital status, insurance status, depression score and maternal
perceived stress score (p-values < 0.005). Pregnant women who smoked during pregnancy were
more likely to be Non-Hispanic white, unmarried, and having public/ no insurance. They were
also more likely to have high depression scores and high perceived stress.
In Tables 2.1 and A2.1 in Appendices, we present the baseline characteristics of the
study sample by the mean and median blood folate levels respectively. The results from
parametric and non-parametric tests were similar. Thus, we reported only the findings from the
parametric tests. The mean folate level was 718.3 ± 183.2 ng/mL, and there was no difference
in folate levels by smoking status. However, statistically significant differences were observed in
the folate level by BMI and trimester of gestation at baseline. Obese women had significantly
higher mean blood folate (741.9 ng/mL) than overweight (714.7 ng/mL) and those with normal
BMI (688.5 ng/mL). Red blood cell folate concentrations were highest among women aged 35
years and older (though not significantly different than levels for other age groups) and women
whose folate level was measured during their second trimester of pregnancy. In the correlation
matrices, folate was found to correlate positively with gestational age at study enrollment (p14

value< 0.001) (Table A2.2. in Appendices), while cotinine correlated positively with depression
and stress scores (Table A2.3. in Appendices).
Table 2.3 shows the adjusted estimates of the association between smoking status
(examined as a binary variable) and folate concentrations from Tobit regression. Non-smokers
had nearly 20 ng/mL higher mean level of folate than smokers, but the difference was not
statistically significant (p-value= 0.4213). In contrast, the association between smoking
examined as a continuous variable and folate levels were statistically significant. Salivary
cotinine levels were significantly associated with decreased erythrocyte blood folate
concentrations (Table 2.4). For every one level increase in cotinine, folate levels reduced by
11.43 ng/mL (p-value=0.032). Gestational age was also found to be associated with folate
concentration. The mean folate levels increased by about 15.5 ng/mL per week in the
periconceptional period (p-value<0.001). Compared to obese women, adjusted blood folate
concentrations were 64 ng/mL (p-value=0.003) lower among women with normal BMI. A
significant negative interaction effect of stress and depression was observed with folate levels
(p-value=0.0083). This indicates that the higher stress scores become, the more negative is the
effect of depression on folate levels. No significant associations were found between maternal
age, marital status, race, insurance and erythrocyte blood folate concentrations.

DISCUSSION
An inverse association between salivary cotinine level and periconceptional red blood
cell folate concentration was found among pregnant women in the early to mid-pregnancy
period. Interestingly, there were no significant differences in the mean folate levels by smoking
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status. We also found a positive gestational age effect. Furthermore, substantial reductions in
folate were also observed among normal weight mothers compared to obese mothers.
Several prior studies have found negative associations between smoking and folate
concentrations among pregnant women13-16; however, few studies have used specific
biomarkers of both tobacco exposure and folate.17 Consistent with our findings, Prasodjo et al17
observed an inverse relationship between tobacco exposure and RBC folate levels in pregnant
women using whole blood biomarkers of folate and smoking but their finding was not
statistically significant. The researchers attributed this result to insufficient statistical power.
The magnitude of the reduction in folate levels they found among women exposed to secondhand smoking (SHS) was lower than that in active smokers-similar to our findings of increasing
cotinine levels associated with lower folate concentrations. However, the authors did not
determine RBC folate, which would have allowed direct comparison with folate status of
women from our study.
We observed no significant differences in mean folate levels by smoking status, and this
result is consistent with previous studies, which reported lower but non-significantly different
folate levels between smokers and non-smokers.16,51 In contrast, earlier studies found smokers
to have significantly lower folate concentrations. 6,8,17 The absence of a significant association
for smoking status, with folate, could be explained by an adequate dietary and supplemental
intake of folate among the participants. Unfortunately, we could not control for confounding
from diet and many other variables in this study. The lack of significant difference found in the
binary form of tobacco exposure variable (smoker vs. non-smoker) might also be attributed to
the well-known statistical problems associated with categorization of continuous variables.
16

Categorization can result in loss of information or statistical power and hide true
relationships.52,53
A positive correlation was observed between gestational age and folate concentrations.
Furthermore, substantial reductions in folate were found among normal weight mothers
compared to obese mothers. Consistent with these findings, a recent cross-sectional study
among pregnant women with similar mean gestational age at enrollment as the sample in this
study (less than 20 weeks), found gestational age to be positively associated with RBC folate.
BMI was also positively related to RBC folate in both of their adjusted and unadjusted analyses.
54

It is important to note that the same study observed a negative (contrasting) association

between gestational age and BMI on serum folate. In previous studies among non-pregnant
women, 55-57 having normal weight was found to be associated with lower concentrations of
RBC folate but higher levels of plasma folate compared to being obese. This was observed
despite evidence of lower folate intake among obese women.55 As a result, our findings must
be interpreted in the context of the folate biomarker used. RBC folate may not reflect freely
available folate at the cellular level in pregnant women because absorption and breakdown of
folate are altered by maternal adiposity.54
Because this study was cross-sectional, our ability to infer causality in the association
between increasing cotinine level and lower RBC folate concentration was limited. Although
several sociodemographic, lifestyle and health-related potential confounders were taken into
account, it was not possible to control for dietary intake of folate, fruits, vegetables, and
alcohol. Folate intake and plasma vitamin C concentrations are known predictors of folate
levels. 58 The direction of the effect of this residual confounding is unclear, however, this may
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be minimal because the participants are of similar income level and may have similar dietary
habits. Another limitation of this study is our inability to generalize the findings to other lowincome populations. Participants were not randomly selected and those who chose to be
included in the study could be different from those who declined. In this instance, the
respondents might be more health conscious and, therefore, findings could be biased towards
the null.
One major strength of the study is the use of validated biomarkers of both the exposure
and outcome. Salivary cotinine analysis is the most sensitive and specific of the three types of
cotinine measures. 39 Most previous studies used self-reported data on smoking or less
accurate measures of cotinine such as serum cotinine. In our study however, folate
concentrations were measured using red blood cell folate, which is a better indicator of longterm folate storage than serum folate.18,19 By measuring RBC folate at less than 21 weeks GA,
we were able to reflect more accurately the periconceptional folate levels among these
women.
Given the role of folic acid in fetal development,25,26 the identification of a modifiable
risk factor associated with low folate concentrations, such as smoking, may offer opportunities
to prevent adverse fetal outcomes and reduce consequent disease risk in adulthood. 27,47,59
Smoking cessation during preconception or periconceptional periods could improve birth
outcomes,60 yet smoking cessation programs during pregnancy are associated with high failure
rates, especially in low-income subpopulations.61,62 This study suggests that smokers may have
a lower RBC folate than non-smokers, and that a significant negative correlation does exist
between cotinine levels and folate concentrations. Thus, higher strength folic acid
18

supplementation in smokers, particularly in those who smoke frequently, might be an avenue
to increase folate concentrations and improve adverse developmental and birth outcomes
linked with tobacco exposure.
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Table 2.1. Baseline characteristics of participants by maternal smoking status (n = 496)

Variables
Overall
Gestational age, mean (SD)
Maternal Age
18–24
25–34
≥35
Maternal Race
Non-Hispanic white
Non-Hispanic black
Other
Marital Status
Married
Unmarried
Insurance Type
Private
Public/ Uninsured
Trimester
First
Second
Body Mass Index∗
<25
25–30
>30
Maternal Depression Score
<12
≥12
Perceived Stress Score
Low
High

Total
n (%)
496 (100.0)

194 (39.1)
245 (49.4)
57 (11.5)

Smokers
n (%)
345 (69.6)
12.3 (3.9)

Non-Smokers
n (%)
151 (30.4)
11.7 (3.7)

134 (38.8)
174 (50.4)
37 (10.7)

60 (39.7)
71 (47.0)
20 (13.2)

P-value
0.1339
0.6538

<.0001
187 (37.7)
186 (37.5)
123 (24.8)

148 (42.9)
140 (40.6)
57 (16.5)

39 (25.8)
46 (30.5)
66 (43.7)
<.0001

87 (17.5)
409 (82.5)

34 (9.9)
311 (90.1)

53 (35.1)
98 (64.9)

34 (6.8)
462 (93.2)

17 (4.9)
328 (95.1)

17 (11.3)
134 (88.8)

0.0003

0.6037
287 (57.9)
209 (42.1)

197 (57.1)
148 (42.9)

90 (59.6)
61 (40.4)
0.5198

156 (31.8)
129 (26.3)
206 (42.0)

111 (32.4)
85 (24.8)
147 (42.9)

45 (30.4)
44 (29.7)
59 (39.9)
0.0005

409 (82.5)
87 (17.5)

271 (78.5)
74 (21.5)

138 (91.4)
13 (8.6)
<0.0001

259 (52.2)
237 (47.8)

154 (44.6)
191 (55.4)

Trimester=Trimester at study enrollment and data collection
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105 (69.5)
46 (30.5)

Table 2.2. Baseline characteristics of the study sample by mean blood folate concentrations
(n = 496)
Variables
Erythrocyte Folate, ng/mL
Overall
Maternal Age
18–24
25–34
≥35
Maternal Race
Non-Hispanic white
Non-Hispanic black
Other
Marital Status
Married
Unmarried
Insurance Type
Private
Public /Uninsured
Trimester
First
Second
Body Mass Index
<25
25–30
>30
Depression Score
<12
≥12
Perceived Stress Score
Low
High
Smoke Tobacco
Yes
No

Mean (SD)
718.3 (183.2)

P-value
0.4091

710.5 (176.1)
717.7 (184.3)
747.4 (200.5)
0.6240
727.6 (188.1)
709.1 (185.9)
718.1 (172.2)
0.9691
717.6 (184.9)
718.4 (183.1)
0.6517
704.6 (152.2)
719. 3 (185.4)
<0.001
668.3 (181.2)
786.7 (163.2)
0.0220
688.5 (177.3)
714.7 (184.9)
741.9 (183.4)
0.5452
718.0 (180.0)
719.6 (202.5)
0.3081
710.2 (186.7)
727.0 (179.4)
0.9700
718.5 (186.9)
717.8 (175.1)

Trimester=Trimester at study enrollment and data collection
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Table 2.3. Adjusted associations between smoking status and maternal periconceptional red
blood folate concentrations (n=496)
Variables
β
SE
p-value
Smoke Tobacco
Yes
17.27
21.17
0.4213
No
ref
Gestational Age
15.26
2.32
<0.001
Maternal Depression Score
12.50
4.92
0.011
Perceived Stress Score
2.48
1.76
0.1575
Race
Non-Hispanic white
ref
Non-Hispanic black
-16.93
20.71
0.4137
Other
-13.30
23.90
0.5779
Body Mass Index∗
>30
ref
<25
-64.91
20.90
0.002
25–30
-29.07
22.14
0.1892
Depression Score*Stress Score
-0.42
0.16
0.010
Adjusted by Tobit regression for gestational age at study enrollment or data collection, perceived stress,
depression, race, & BMI at enrollment. β= Estimate; SE= Standard error; ref= Reference group.
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Table 2.4. Adjusted associations between cotinine levels and maternal periconceptional red
blood folate concentrations (n=496)
Variables
β
SE
p-value
Baseline cotinine
-11.43
5.45
0.0320
Gestational age
15.53
5.33
<0.001
Maternal Depression Score
13.13
4.90
0.007
Perceived Stress Score
2.81
1.75
0.109
Race
Non-Hispanic white
ref
Non-Hispanic black
-25.00
21.10
0.235
Other
-23.10
24.07
0.337
Body mass index∗
>30
ref
<25
-64.34
20.88
0.002
25–30
-28.84
22.10
0.191
Depression Score*Stress Score
-0.42
0.16
0.007
*Adjusted by Tobit regression for gestational age at study enrollment or data collection, perceived stress,
depression, race, & BMI at enrollment. β= Estimate; SE= Standard error; ref= Reference group.
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Percentage

Figure 2.1. Distribution of periconceptional erythrocyte folate concentrations (ng/ml)
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CHAPTER THREE:

MANUSCRIPT 2: EFFICACY OF HIGHER-STRENGTH FOLIC ACID ON FETAL BODY SIZE AMONG
WOMEN WHO SMOKED DURING PREGNANCY

ABSTRACT
Despite evidence of a causal association between smoking in pregnancy and
intrauterine growth restriction, a plausible relationship between tobacco use and low maternal
folate and a possibility of folic acid supplement improving birth outcomes among smokers, no
experimental study has investigated the benefit of folic acid in reducing the adverse effects of
maternal smoking on fetal outcomes. In this study, we examined the efficacy of higher-strength
folic acid supplementation in combination with smoking cessation programs in preventing a
reduction in fetal body size among smoking pregnant women. Primary data from a doubleblinded randomized controlled trial which utilized validated tools and biomarkers were
analyzed. Participants were pregnant women who received antenatal care at the Genesis Clinic
of Tampa between 2010-2015. A total of 345 pregnant smokers were enrolled in the study at a
gestational age of less than 21 weeks and were followed until delivery.
All primary analyses were conducted on a modified intention-to-treat basis and included
participants who completed the trial with an observed endpoint, irrespective of compliance to
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protocol. The relative risks of having an SGA neonate among mothers who had the high dose
treatment vs. standard dose of folic acid was estimated using a log-binomial regression model.
Mean differences in infant birthweight between treatment groups was assessed using multiple
linear regression analysis.
The baseline characteristics of the participants in the two treatment groups were well
matched with the exception of race. The incidence of SGA was 21.4% (n=74), and the mean
(±SD) infant weight at birth was 3059.0g (±640.2). Smokers on high-dose folate during
pregnancy had infants with a 140.38g higher birth weight than their counterparts on standard
dose folate (P =0.047). Mothers who received higher strength folate had a 31.0% lower risk of
having babies with SGA compared to their counterparts on the standard-dose (adjusted relative
risk-ARR=0.69, 95% CI: 0.46–1.03; (P =0.073)).
In conclusion, higher strength folic acid supplementation in pregnant women who
smoke might be a safe and cost-effective way to improve birth outcomes and reduce low birth
weight and SGA associated infant morbidity and mortality.

INTRODUCTION
In spite of knowledge of the health risks of tobacco smoking and numerous programs
aimed at getting people to quit, smoking continues to be quite common among the general
population and pregnant women. Recent studies have estimated the rate of smoking to be
approximately 14-24% among nonpregnant U.S. women of reproductive age.34,63,64 During
pregnancy, these rates decrease to between 7-12%,3,34,64 and many infants remain exposed to
the adverse effects of cigarette smoke in utero.
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Maternal smoking is causally associated with intrauterine growth restriction, 1,3,5 and
increases the risk of preterm birth and low birth weight.20,64-68 A recent population-based study
found that newborns of active tobacco smokers compared to those of non-smokers were more
likely to weigh less (3150±759 g vs. 3377±604 g, P<0.05).69 Infants born preterm, low birth
weight or small for gestational age (SGA) have an increased risk of neonatal complications and
infant mortality.70,71 Furthermore, low birth weight and SGA births have been implicated in
contributing significantly to adult-onset disorders such as hypertension, type 2 diabetes,
cardiovascular diseases and metabolic syndrome.72-74 Tobacco use in pregnancy increases the
risks of future health complications,20,75,76 creates a burden for families,77 and increases health
care cost.77-79
The negative impact of smoking on folate metabolism and diet quality including folate
intake has been well documented in the literature.9,10 Smokers have lower blood folate
concentrations than nonsmokers.6,8,17 Low folate intake and reduced red blood cell (RBC) folate
levels in the late pregnancy increase the risk of SGA birth and low birthweight.8,11 However,
numerous studies suggest a possible benefit of maternal folate consumption or blood folate
levels on birth weight.8,12,80 Clinical observations have shown that taking folic acid throughout
pregnancy prevents the premature delivery of small-for-gestational-age infants.81 Furthermore,
in a review of randomized clinical trials (RCTs) investigating the effect of folic acid
supplementation on birth weight, a significant dose-response association between folate intake
and birth weight was observed.32
A reduction in low birth weight and SGA will significantly help reduce infant morbidity
and mortality and curb associated healthcare cost. Tobacco exposure is a modifiable risk factor
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that improves birth outcomes82,83; however, smoking cessation programs during pregnancy are
associated with high failure rates especially in low-income subpopulations.61,62 Folic acid, a
growth stimulating nutrient which is reduced in mothers who smoke during pregnancy is
another modifiable protective factor that has been found to improve birth outcome in both
pregnant women generally and in smokers. In the Generation R European study, Bakker et al23
found that folic acid supplements might reduce some of the adverse effects of maternal
smoking on fetal growth and neonatal outcomes. The researchers concluded that the results
from their observational study should be considered hypothesis-generating and be confirmed
using randomized controlled trials.23
Despite evidence of a causal association between smoking in pregnancy and
intrauterine growth restriction,1-3,5 a plausible relationship between smoking and low maternal
folate6-8,17 and a possibility of folic acid supplements improving birth outcomes among
smokers,23 no experimental study has investigated the benefit of folic acid in reducing the
adverse effects of maternal smoking on fetal outcomes.
In this study, we examined the efficacy of higher-strength folic acid in combination with
smoking cessation programs in preventing a reduction in fetal body size among smoking
pregnant women. Primary data from a double-blinded randomized controlled trial which
utilized validated tools and biomarkers were analyzed. We hypothesized that mothers on
higher-strength folic acid versus standard of care folic acid would have infants with higher birth
weight and lower risks of small for gestational age (SGA).
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METHODS

Trial Population and Design
This was a randomized, double-blind, controlled clinical trial in which 345 smoking
pregnant mothers underwent randomization. Eligible participants were randomly assigned in a
1:1 ratio to receive either 0.8mg/day of folic acid (standard of care) or 4mg/day of folic acid
(higher-strength). The folic acid tablets had exactly the same color, shape, size, and were
packed in identical coded bottles. The code was the only distinguishable feature which was
used to determine whether the bottle contained a 0.8 mg or 4 mg folic acid tablet. This code
was concealed with patient ID labels. The physicians, laboratory staff, study investigators and
study participants were masked to the treatment groups.
Randomization was performed by a biostatistician through a computer-generated
randomization schedule, using a permuted block design with a block size of 12. This type of
design was chosen to allow balance in the number of participants in each group at the end of
the clinical trial. The coded randomization schedule was properly stored in a sealed envelope
within a locked file cabinet. In addition to the intervention, both study arms received
preparations of multi-vitamins that did not contain folic acid and were enrolled in the smoking
cessation program at the study site.
Participants were recruited between 2010-2015 at the Genesis Clinic Tampa, a
community health center affiliated with the Department of Obstetrics and Gynecology of the
University of South Florida (USF). Almost all the pregnant women who receive antenatal care at
the Genesis Clinic deliver their babies at the USF Department of Obstetrics and Gynecology at
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Tampa General Hospital because of reduced cost of delivery for low-income women at this
location. This made it easier to track patients and retrieve their birth data, thereby reducing
loss to follow-up.
Women were eligible for participation in the study if they were (1) current smokers (2)
ages 18-44 years; (3) less than 21 weeks gestation as confirmed by last menstrual period; and
(4) residents of Tampa, Florida, or a surrounding area, to facilitate follow-up and reduce
attrition rate. To identify pregnant women who smoked at baseline, screening for cotinine was
done using saliva (a biological marker for nicotine). Women who had at least a cotinine level of
1 (detectable cotinine) were eligible for the study. Participants were excluded if there was
evidence of an indication for chronic blood transfusion and treatment with anticonvulsant
medication. Women receiving chronic blood transfusion may have inaccurate measures of
folate RBC levels, due to transfused red blood cells (RBC). Patients treated with anticonvulsants
may have folic acid deficiency as side effects of the medication.37 Table A2.4. in Appendices
shows the schedule of data collection, instruments, and procedures used in this trial. Study
questionnaires and salivary cotinine laboratory assessments were completed during the three
study visits. At delivery, cotinine level was further evaluated, and fetal body measurements
were taken.
Written informed consent was obtained from all the participating women before trialrelated procedures were initiated at screening and enrollment. Informed consent was available
in both English and Spanish. The study was funded by the James and Esther King Biomedical
Research Program, Florida Department of Health (grant numbers 4KB03 and 1KG14-33987). The
trial protocol was approved by the Institutional Review Board of the University of South Florida.
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Smoking Cessation Program
All women enrolled in the trial signed a contract stating they agreed to commit to
quitting smoking, and attended at least one smoking cessation session at the study site for
smoking mothers or called the Florida Quit Line. The counseling sessions focused on the
following; (1) receipt of self-help materials and how to make a quit attempt, (2) effects of
secondhand smoke, partners who smoke and tips on how to establish smoke-free homes and
cars, (3) stress management and benefits of not smoking, and (4) prevention of smoking
relapse. Women who persistently tested positive to salivary cotinine were referred by study
personnel to Florida’s QuitLine, a toll-free telephone-based tobacco use cessation service.
Additionally, all women were linked to community smoking cessation services such as the
Hillsborough County Healthy Start program, a free, voluntary and intensive smoking cessation
program.

End-Point Measures
The primary endpoint in this study was small for gestational age (SGA). SGA was defined
as infants weighing below the 10th percentile of birth weight for their gestational age using
normalized growth curves.84 Gestational age was based on dating ultrasound at first prenatal
visit and the date of delivery of the baby. The secondary outcome was birth weight measured in
grams at delivery.
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Covariates
These variables which were used to describe the baseline characteristics of the study
population include sociodemographic factors (such as maternal age, race, marital status, and
insurance status), lifestyle factors (such as cotinine level, alcohol consumption, and maternal
body mass index (BMI)), and perinatal factors such maternal depression, stress, gestational age
and maternal chronic diseases such as hypertension and diabetes.
Sociodemographic and lifestyle factors were extracted from participants’ medical
records, specifically the American College of Obstetrics and Gynecology (ACOG) form. This form
is routinely used at the study site to document mothers’ information such as demographic,
obstetric and gynecologic history, and results of physical and laboratory examinations.
Race/ethnicity was categorized into three groups: non-Hispanic black (black), non-Hispanic
white (white), and other (includes Hispanic). Age was defined as both continuous and
categorical variable (grouped as 18-14, 25-34 and ≥35 years). Marital status was dichotomized
as either married or unmarried; the latter included divorced, separated and unknown marital
status. Health insurance was categorized as private or public/uninsured. BMI was calculated
using maternal self-reported pre-pregnancy weight and height measured at enrollment. BMI
was calculated as weight (kg)/ height (m)2 and categorized into normal (<25·0kg/m2),
overweight (25·0–29·9kg/m2) and obese (≥30·0kg/m2). Although 5 women had BMI below 18.5
(underweight), they were included in the normal BMI group due to limited sample.
Depression was assessed using the Edinburgh Postnatal Depression Scale (EPSD). This is
a validated tool for assessing ante-natal and post-natal depressive symptoms depression
measurement.44 Mothers who score above 12 or 13 on the scale are likely to be suffering from
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depression.45 We dichotomized this variable as high and low, using a cut-off point of 12. Stress
was measured using the Perceived Stress Scale (PSS-14) scale, which is a validated tool for
comparisons between people in study samples.46 As a result, women who had a score equal to
or greater than the mean stress score for the sample were classified as having high-stress
levels, while those who had a score below the mean were classified as having low-stress levels.
Cotinine was measured by a test of maternal saliva for the presence of cotinine with the
use of a rapid semi-quantitative screening test called NicAlert (Jant Pharmacal Corporation,
Encino, CA). Salivary cotinine analysis is the most sensitive and specific of the three types of
cotinine measures.78 This method has a sensitivity of 99% and specificity of 82%. The cotinine
test strip displays seven levels (0-6), each of which represents a range of salivary cotinine
concentrations. Higher levels on the strip indicate a higher range of cotinine. Based on the
manufacturer’s guidelines, individuals with a reading of at least level 1 result are considered
smokers. Cotinine level was also treated as a continuous variable in our analysis.

Statistical Analysis
The parent grant was designed with a sample size of 400 women and an expectation of
following up 320 participants until delivery. These numbers were estimated from a sample size
calculation conducted to evaluate the efficacy of higher-strength folic acid in combination with
smoking cessation programs in preventing a reduction in the trial’s primary outcome; small for
gestational age. The following were the assumptions used: (1) a type 1 error rate of 5%; (2)
power of 80%; (3) an incidence of 14% SGA as reported by among mothers that receive services
mostly from the study site; (4) an effect size of 2.0 based on the parent grant’s pilot data that
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found that the percentage of DNA-hypomethylation in placental tissues from smoking mothers
was 2.5 times that of non-smokers; (5) a 20% attrition rate. In this study, outcome data was
available for 312 participants, and this translates to a power of 78%.
We assessed the differences in the baseline sociodemographic, lifestyle and healthrelated characteristics of study participants by their treatment groups. Means of continuous
data were compared using independent t-tests or ANOVA, while categorical variables were
compared using the chi-square test. Using the intention-to-treat (ITT) population, birth
outcomes for all study participants were described using frequencies and percentages. ITT
population includes all randomized participants in the groups to which they were randomly
assigned, irrespective of their adherence to the treatment, regardless of the treatment they
actually received, and regardless of withdrawal from treatment or deviation from the study
protocol.85 All primary analyses were conducted on a modified intention-to-treat basis and
included participants who completed the trial with an observed endpoint, irrespective of
compliance to protocol. Excluded were abortions/miscarriages, fetal demise, and still births
because the endpoints were not observed, and congenital anomalies or multiple births because
growth potentials for those fetuses may not be comparable to normal singleton fetuses.
Twenty-six cases (n=26) were excluded, therefore leaving the total participants eligible to be
included in the modified intention-to-treat analyses as 319. Two hundred and forty-six (n=246)
women were followed until delivery at Tampa General Hospital, and additional birth data (such
as birthweight, gestational age, and gender of the neonate) were retrieved from medical
records during postnatal follow-up for 66 participants. For both of our primary and secondary
endpoints, outcome data were obtainable for a total of 312 subjects, representing 97.8% of the
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population eligible for inclusion in the modified intention-to-treat analysis. Due to loss to
follow-up, data was unavailable for 2.2% (n=7) of the eligible population.
Since there were four repeated measures of cotinine level from participants during the
trial, the decision was made to identify the unique paths of cotinine levels throughout the
pregnancy. Group-based latent class trajectory model, a semiparametric method, used to
discover patterns, was utilized. This approach offers a data-driven method to identify distinct
individual patterns of a variable of interest and the corresponding probability of falling into
each pattern, also known as the posterior probability.86 Trajectory analyses were conducted,
and participants were then classified into groups based on their highest posterior probability.
The fit of five models, with two to six subgroups, were compared by applying all linear
terms and quadratic terms (Table A2.5 in Appendices). Model 4 had the highest Bayesian
information criterion (BIC), but the log Bayes factor approximation (2(∆BIC)) comparing the
three-group model to the four-group model was low (4.4 and 3.8 for linear and quadratic terms
respectively). According to the criteria for the log Bayes factor approximation,87 there is no
strong evidence against the null three-group model when comparing the two models, so the
three-group model has a better fit. Therefore, it appears that three groups is the optimal
number of latent cotinine subgroups. We also determined the polynomial degree for each
trajectory in the three-group model by investigating every permutation of both linear and
quadratic terms ((Table A2.6 in Appendices). We sorted from the best to worst model, based on
Bayesian information criterion (BIC). Consequently, model one was chosen as the best
combination of polynomial degrees for the three-group cotinine model, namely high, moderate
and low cotinine levels. The discriminated cotinine group identified was included in our
35

analyses as a group variable representing cotinine trajectory. All statistical tests were two-tailed
with a type 1 error rate fixed at 5%. Statistical analyses were conducted in SAS (SAS Institute,
Inc., Cary, North Carolina, version 9.4).

Small for Gestational Age (SGA)
The chi-square test was used to compare crude frequencies and percentages between
maternal and fetal characteristics with respect to the outcome. Relative risks of having an SGA
neonate among mothers who had the high dose treatment vs. standard dose was estimated
using a log-binomial regression model. Race was adjusted for in the model because it was not
balanced across treatment groups at baseline. Cotinine group trajectory was also included in
the model to account for possible changes in cotinine levels during the course of pregnancy.
Relative risks (RR) and 95% confidence intervals reported.

Birthweight
This continuous variable was assessed for normality, and the distribution was close to
symmetrical and assumed to be approximately normal (Fig A2.1 in Appendices). The measures
of central tendency also showed that the mean, median and mode were very similar (data not
shown). Independent t-tests and ANOVA were used to compare birth weight between the trial
treatment groups and participants’ characteristics. Multiple linear regression analysis was
conducted, adjusting for race and cotinine group trajectory. Mean differences and standard
errors were reported.
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RESULTS
Figure 3.1 describes the enrollment and follow-up of the participants. A total of 345
smoking pregnant women were enrolled in the trial; 171 women were randomly assigned to
the high-dose folate and 174 to standard dose folate. Of these women, birth outcome data was
available for 312 (90.4%), and this represents the number of participants included in the
modified intention to treat (mITT) analysis. For the mITT population, 152 women were in the
high-dose folate group and 160 in the standard dose folate group.
In Table 3.1, we present the sociodemographic, lifestyle and health-related
characteristics of study participants by folate dose treatment received. The baseline
characteristics of the participants in the two groups were well matched with the exception of
race. Women of ‘other’ race were more likely to be assigned to the standard of care. The mean
(±SD) age of participants was 26.7 (±5.6) years, and the trial population was predominantly
made up of single/divorced (90.1%) and women without insurance or on public insurance plans
(95.1%). Approximately two-thirds of the population was either overweight or obese (67.7%),
and about one-third had hypertension (34.3%) or diabetes (32.7%).
Table 3.2 shows a description of the overall birth outcomes in the intention to treat
population. The total number of live births was 312 (90.4%), and the incidence of SGA was
21.4% (n=74). Among the mothers in the trial, SGA birth was recorded in 30 (17.5%) infants in
the high-dose folate group and 44 (25.3%) in the low-dose folate group (P =0.079). There were
marginal differences in SGA risk by treatment group but not in the rate of live births (P =0.427).
In all modified intention-to-treat analyses conducted in this study, we excluded 26 participants
(7.5%) for the following reasons: pregnancies that ended up in induced abortion/miscarriage
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(n=12), congenital anomaly (n=2), fetal demise (n=5), stillborn (n=3), and multiple gestations
(n=4). There were no statistical differences in the rate of excluded birth outcomes and live
births by treatment group (Table 3.2).
Figure 3.2 illustrates the longitudinally-derived cotinine trajectories for trial participants.
We discriminated three distinct groups of maternal cotinine velocities; one with a consistently
high level of cotinine, another with a low level and the third group with moderate cotinine level
but a marked decline towards the end of gestation. Approximately 18.9%, 48.3% and 32.8% of
the study participants were classified respectively into the groups stated above. At the end of
the study, only 3.0% of the women with cotinine data at delivery (n=8) had stopped smoking
(cotinine level of zero).
In Table 3.3, we present the results of the maternal and fetal characteristics of the study
participants by crude mean birthweight. The overall mean (±SD) infant weight at birth was
3059.0g (±640.2), and there were significant differences by treatment, cotinine group and illicit
drug use (P <0.05). Mothers who received high-dose folate, had low cotinine trajectory and
never abused drugs during pregnancy had babies with higher birth weight. There were no
significant differences in birthweight by other selected characteristics.
In Table 3.4, we present the results from the multivariable linear regression of the effect
of treatment on birthweight. Smokers on high-dose folate during pregnancy had infants with a
140.38g higher birthweight than their counterparts on standard dose folate (P =0.047).
Compared to mothers with low cotinine levels, mothers with high or moderate cotinine levels
had babies with approximately 435g and 205g significantly lower birth weight. Additionally,
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babies of black mothers and mothers of ‘other’ race weighed over 200g less than infants born
to white mothers (P <0.05).
A comparison of maternal sociodemographic and health-related characteristics by SGA
within the trial population is presented in Table 3.5. Mothers with SGA babies were more likely
to be older, have higher baseline cotinine level, use illicit drugs in pregnancy and have a
consistently high/moderate cotinine level during pregnancy (P <0.05). There were no significant
differences in SGA by other selected maternal and fetal characteristics.
In Table 3.6, we present results from the log-binomial model estimating the risks of SGA.
Smokers during pregnancy who were assigned high-dose folate had a 31.0% lower risk of having
babies with SGA compared to their counterparts on the standard-dose (adjusted relative riskARR=0.69, 95% CI: 0.46–1.03; (P =0.073)). Black mothers had approximately 51% higher risk of
SGA babies than white mothers, and this association was marginally significant (ARR=1.51, 95%
CI: 0.99–2.31, P =0.058). Additionally, mothers with high and moderate cotinine trajectory
levels were 2.5 times and 1.9 times respectively more likely to have SGA babies than mothers
with low cotinine levels.

DISCUSSION
In this randomized clinical trial, we examined the efficacy of 4mg/ day dose of higherstrength folic acid versus 0.8mg/ day dose of folic acid (standard dose) in reducing the risk of
small for gestational age (SGA) and increasing birth weight among low-income mothers who
smoked during pregnancy. We observed a 31% lower risk of small for gestational age (SGA)
birth among mothers on high dose folate, with a trend towards statistical significance (P
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=0.073). Mothers on high-dose folate had babies with a significantly higher birth weight (140g)
than those on standard folate dose in the adjusted model. Another finding in our trial was a
dose-response effect of cotinine trajectory on both an increase in the risk of SGA and a
decrease in birth weight. As in other studies, black mothers had infants who weighed
significantly lower at birth and had increased risk of SGA than white mothers.88, 89 It is worthy of
note that no prior experimental study has been conducted to investigate the efficacy of folic
acid on improving birth outcomes among smokers.
Previous observational studies have identified a protective effect of folic acid
supplements on the risk of SGA among women of reproductive age, in general. 23,90-92 Similar to
our findings, a population-based cohort study found in their subgroup analyses of women who
continued to smoke during pregnancy, that participants who took no folic acid supplement had
a 29% higher odds of SGA than their counterparts who took 0.4–0.5 mg/day folic acid
supplement [odds ratio 1.29 (95 % confidence interval 0.69, 2.42)]. It is important to note that
Bakker and colleagues23 compared no folate supplement to standard of care dose in their study
while we compared standard of care dose to higher strength folate. Even though our findings
and those of Bakker et al23 were not statistically significant, they suggest that the adverse effect
of maternal tobacco smoking on SGA may be reduced by folic acid supplementation. Unlike the
Bakker et al23 study that used self-report to assess folic acid intake, we randomly assigned
women to folic acid treatment, thereby reducing the possibility of misclassification and type 2error. In our trial, folic acid treatment was commenced in the first trimester/ mid-pregnancy
(less than 21 weeks gestation), and this might account for a lower effect of treatment on SGA
risk. A recent meta-analysis of cohort studies reported that folic acid supplementation initiated
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preconceptionally was more protective against SGA births than supplementation started after
conception.90 Another systematic review and meta-analysis found that folate supplementation
only significantly reduces the risk of SGA birth if commenced before conception.92
In several published works, including a systematic review of randomized clinical trials,
significant positive associations between folate intake and birth weight were observed.8, 32, 80,
92,93

However, these studies included women of reproductive age in general; smokers and non-

smokers, limiting our ability to compare findings. The result from the current study
demonstrated a positive effect of high dose folate on birth weight among smokers during
pregnancy. Similar to our findings, Bakker et al23 found a mean difference of 112g in birth
weight among a subgroup analysis of smokers who did not use folic acid supplement vs. those
who used 0.4mg/day in the periconceptional period [-112 (95 % confidence interval -187, 370)]. Our study builds on this observational study that compared no folic vs. folic acid
supplement and provides evidence that higher dose folate may increase birth weight among
women who smoke in pregnancy.
We observed a dose-response gradient of cotinine trajectory groups on the risk of SGA
and low birth weight. Higher cotinine group was associated with worse birth outcomes. This
finding is novel; studies have generally not examined the effect of cotinine trajectory on birth
outcomes among smokers. Previous studies that have investigated the effect of smoking on
birth outcomes assessed tobacco exposure at one time point.67,94 or at multiple time points20
without taking into consideration cotinine groups or patterns. Similar to the dose-response
effect observed in our study, previous observational studies that utilized cross-sectional
assessments of smoking reported an increase in adverse birth outcomes by cotinine
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concentrations.94 Maintaining lower levels of smoking among women of reproductive age who
are unable to quit seems beneficial in reducing SGA birth and low birth weight.
Infants of Black mothers who smoked during pregnancy had a higher risk of small SGA
and lower birth weight compared to infants of their white counterparts. Because of the limited
number of SGA cases, we could not access the modification effect of treatment on the
association between race and SGA. Even though our trial was restricted to smokers, our
findings are similar to previous reports in the United States that black infants, in general, have
worse birth outcomes. 88-89 They have consistently had lower birth weight than Whites, and this
disparity has remained for decades.89, 95 Studies have suggested that these White-Black
disparities are due to pathological, rather than genetic restrictions in fetal growth.96,97 The
adverse intrauterine environment in which black fetuses grow might reflect prolonged and
accumulated experiences of racial discrimination or other sources of psychological stress.96-98
In this trial, we did not observe significant differences in the percentages of mothers
with adverse birth outcomes such as spontaneous abortion and stillbirth between the
treatment groups in a bivariate analysis (P >0.500). Folic acid is a water-soluble Vitamin B
substance and is safe in pregnancy at the dose used in the trial.100 Doses as high as 5mg/day
and greater have been used in previous growth studies with no apparent adverse effects. 93,99
However, an epigenetic study has demonstrated possible effects of folic acid supplementation
on the genome of the offspring.101 Thus, long-term follow-up of the infants of study participants
exposed to higher-strength folate would be beneficial. Close monitoring for safety and adverse
events associated with higher strength folate in future studies will be necessary. Overall, larger
studies will be required to confirm or refute our findings and examine the effect of high
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strength folic acid in reducing adverse birth outcomes especially among high-risk subgroups
such as Black women.
This study has several important limitations. First, we did not assess or control for the
effect of diet, a possible confounder in this study. However, randomization was conducted and
there is reduced likelihood of differences in the diet by treatment groups. Even though we
estimated a power of 78% to detect a difference in SGA risk, the confidence interval was quite
narrow indicating precision and stability of the estimates. As with most clinical trials, the
generalizability of our findings to an external population is an issue. Voluntary participants in
studies are usually different from nonparticipants. However, our results may be applicable to
low-income women who smoke during pregnancy.
There are numerous strengths of this trial. The use of double-blind, randomized clinical
trial allows for causal inference. Even though we had a relatively high percentage of women lost
to follow-up, we were able to retrieve their outcome data from medical records, thereby
minimizing information bias due to follow up. The efficacy of folate in the modified intentionto-treat population (31.0%), may more closely represent the effectiveness under real-world
conditions. A per-protocol analysis, a type of analyses which exclude participants who deviate
from the protocol could have produced more significant findings. To our knowledge, this is the
first randomized control trial to report the effect of high strength folic acid in combination with
enrollment in smoking cessation program in preventing adverse birth outcomes among
smokers in pregnancy.
In conclusion, higher strength folic acid supplementation may have the potential to offer
smoking pregnant women a safe, easy and convenient option for reducing their risk of adverse
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birth outcomes. The achievement of a higher infant birth weight in smoking mothers on high
strength folic acid is significant for this high-risk group. Additionally, the possibility of a
decrease in SGA births by approximately 31% would be huge considering the number of cases
of SGA births that can be prevented, and the subsequent reduction of burden on families and
the health care system. Higher strength folic acid supplementation in pregnant women who
smoke might be a cost-effective way to improve birth outcomes and reduce low birth weight
and SGA associated infant morbidity and mortality.
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345 women underwent
randomization

Baseline: 171 were
assigned to receive 4mg
of folic acid once daily

Baseline: 174 were
assigned to receive
0.8mg of folic acid once
daily

19 Lost to follow-up
7 Fetal loss

7 Fetal loss
Visit 2: 149 participants
attended follow-up visit

Visit 2: 145 participants
attended follow-up visit

4 Lost to follow- up

8 Lost to follow-up
Visit 3: 137 participants
attended follow-up visit
11 Lost to follow-up
or delivered outside
of center, 4 Fetal
loss, 1 Congenital
anomaly, 2 Multiple
gestation

18 Lost to follow

Visit 3: 145 participants
attended follow-up visit

119 Completed study
with birthweight data

127 completed study
with birthweight data

13 Lost to follow-up
or delivered outside
of center, 2 Fetal
loss, 1 Congenital
anomaly, 2 Multiple
gestation

33 Birthweight data
retrieved during
postnatal follow-up

33 Birthweight data
retrieved during
postnatal follow-up
160 Total participants
with birthweight data
were included in the
modified intention to
treat analysis

152 Total participants
with birthweight data
were included in the
modified intention to
treat analysis

Figure 3.1. Enrollment, randomization, and follow-up of participants
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Table 3.1. Baseline socio-demographic, lifestyle and health-related characteristics of all
randomized study participants by folate treatment (n=345)
Variables
High-Dose
Standard Dose P-valueb
Folate (N=171) Folate (N=174)
a
N
(%)
Count (%)
Count (%)
Age in years
26.7±5.6
26.4±5.1
27.3±5.8
0.1035
Gestational age
12.3±3.9
12.4±3.9
12.2±3.9
0.5721
Baseline Cotinine
2.9±1.4
3.0±1.5
2.9±1.4
0.3535
Race
0.0274
White
148 (42.9) 78
(45.6) 70
(40.2)
Black
140 (40.6) 74
(43.3) 66
(37.9)
Other
57
(16.5) 19
(11.4) 38
(21.8)
Marital Status
0.255
Married
34 (9.8)
20
(11.7) 14
(8.05)
Single/ Divorced
311 (90.1) 151
(88.3) 160
(91.9)
Spanish Speaking
Yes
21
(6.1)
8
(4.7)
13
(7.5)
0.2780
No
324 (93.9) 163
(95.3) 161
(92.5)
Insurance
0.4336
Public/None
328 (95.1) 161
(94.1) 167
(96.0)
Private
17
(4.9)
10
(5.9)
7
(4.0)
BMI
Not overweight
111 (32.4) 53
(31.0) 58
(33.7) 0.1239
Overweight
85
(24.8) 36
(21.0) 49
(28.5)
Obese
147 (42.9) 82
(47.9) 65
(37.7)
Alcohol Use
Yes
30
(9.5)
18
(11.2) 12
(7.6)
0.2727
No
287 (90.5) 142
(88.7) 145
(92.4)
Illicit Drug Use
Yes
94
(31.0) 50
(32.9) 44
(29.1) 0.4798
No
209 (69.0) 102
(67.1) 107
(70.9)
Stress Score
High
191 (55.4) 95
(55.6) 96
(55.2) 0.9498
Low
154 (44.6) 76
(44.4) 78
(44.8)
Depression Score
High
63
(18.3) 31
(18.1) 32
(18.4) 0.9498
Low
282 (81.7) 140
(81.9) 142
(81.6)
Hypertension
Yes
113 (34.3) 54
(33.1) 59
(35.5) 0.6449
No
216 (65.7) 109
(66.9) 107
(64.5)
Continued on next page
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Table 3.1. (Continued)
Variables
Diabetes
Yes
No
Heart Disease
Yes
No

High-Dose
Folate (N=171)

Standard Dose
Folate (N=174)

P-valueb

108
222

(32.7)
(67.3)

52
111

(31.9)
(68.1)

56
111

(33.5)
(66.5)

0.7522

42
286

(12.8)
(87.2)

22
141

(13.5)
(86.5)

20
145

(12.1)
(87.9)

0.7093
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Table 3.2. Birth outcomes for study participants in the intention-to-treat population (n=345)
Event
High-Dose Folate Standard Dose Folate P-value
(N= 171)

(N= 174)

no. of participants (%)
Small for Gestation Age

30 (17.5)

44 (25.3)

0.0798

Singleton live birth

152 (88.9)

160 (91.9)

0.4272

Induced abortion/miscarriage 6 (3.5)

6 (3.4)

0.9755

Congenital anomaly

1 (0.6)

1 (0.6)

1.0000

Fetal demise

3(1.7)

2 (1.1)

0.6830

Still born

2 (1.2)

1 (0.6)

0.6206

Multiple gestation

2 (1.2)

2 (1.1)

1.0000

*Complete loss to follow-up

5 (2.9)

2 (1.1)

0.2791

*Indicates delivery records that were not available or retrievable.
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Figure 3.2. Longitudinal-derived cotinine trajectories in the modified intention-to-treat
population (n=319)
Each straight line reflects separate cotinine trajectory: 1-low level; 2-moderate level; and 3-high
level.
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Table 3.3. Maternal and fetal characteristics of the trial sample by mean birthweight (N = 312)
Variables
Overall
Treatment
High-dose
Low- dose
Maternal Age
18–24
25–34
≥35
Maternal Race
Non-Hispanic white
Non-Hispanic black
Other
Marital status
Married
Unmarried
Insurance Type
Private
Public /Uninsured
Trimester
First
Second
Body mass index
<25
25–30
>30
Cotinine group
Low
Moderate
High
Depression Score
<12
≥12
Perceived Stress Score
Low
High

Mean (SD)
3059.0 (640.2)

p-value
0.0457

3133.3 (608.5)
2988.5 (663.2)
0.2679
2928.7 (802.9)
3073.1 (631.0)
2944.0 (711.1)
0.0608
3150.9 (625.5)
3012.2 (568.8)
2928.7 (802.9)
0.0890
3235.3 (684.1)
3037.5 (632.6)
0.9946
3054.3 (390.1)
3055.0 (648.4)
0.4665
3035.5 (684.9)
3087.8 (581.8)
0.1372
2983.5 (581.4)
3014.4 (730.1)
3142.7 (621.6)
0.0015
3175.7 (613.7)
3028.8 (660.7)
2819.4 (601.2)
0.0804
3089.3 (627.1)
2926.4 (684.9)
0.1788
3111.9 (556.6)
3016.0 (699.6)
Continued on next page
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Table 3.3. (Continued)
Alcohol Use
Yes
No
Illicit Drug Use
Yes
No
Hypertension
Yes
No
Diabetes
Yes
No
Heart Disease
Yes
No
Gender of child
Female
Male

0.2156
3097.8 (617.9)
2963.6 (706.6)
0.0034
2909.4 (686.4)
3159.0 (582.8)
0.3286
3051.5 (618.2)
3098.6 (625.4)
0.5634
3107.3 (606.8)
3075.2 (619.6)
0.8515
3061.6 (620.3)
3082.2 (625.4)
0.3448
3039.4 (543.4)
3111.4 (729.9)

Trimester=trimester at study enrollment and data collection; Cotinine group=cotinine trajectory group
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Table 3.4. Adjusted effect of folate treatment on birthweight (g) among trial population
(n=312)
Variables
β
SE
p-value
Treatment
High dose

140.39

70.52

0.0474

Low dose

ref

-

-

High

-434.90

79.45

<0.0001

Moderate

-205.40

99.78

0.0102

Low

ref

-

-

Black

-224.01

78.98

0.0049

Other

-264.94

103.43

0.0109

White

ref

-

-

Cotinine group

Race

*Adjusted for cotinine group trajectory and race. β= Estimate; SE= Standard error; ref= Reference group.
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Table 3.5. Maternal and infant characteristics by small for gestational age (n=312).
Variables
SGA (N=72)
NO SGA (N=240)
P-valueb
Count
(%)
Count
(%)
Age in years
28.5±5.4
26.6±5.7
0.0095
Gestational age
38.3±1.9
38.4±2.6
0.7758
Baseline Cotinine
3.5±1.5
2.8±1.4
0.0007
Race
0.5069
White
29
(40.3)
107
(44.6)
Black
33
(45.8)
92
(38.3)
Other
10
(13.9)
41
(17.1)
Marital Status
0.1301
Married
4
(5.6)
30
(12.5)
Single/ Divorced
68
(94.4)
210
(87.5)
Insurance
0.5414
Public/None
67
(93.1)
228
(95.4)
Private
5
(6.9)
11
(4.6)
BMI
0.4874
Not overweight
26
(36.6)
72
(30.1)
Overweight
19
(26.8)
62
(25.9)
Obese
26
(36.6)
105
(43.9)
Alcohol Use
0.6729
Yes
6
(10.7)
17
(8.8)
No
17
(89.3)
175
(91.2)
Illicit Drug Use
0.0141
Yes
25
(43.9)
52
(29.1)
No
32
(56.1)
142
(70.9)
Cotinine Group
0.0044
High
20
(27.8)
36
(15.0)
Moderate
30
(41.7)
82
(34.2)
Low
22
(30.6)
122
(50.8)
Stress Score
High
42
(58.3)
130
(54.2)
0.5330
Low
30
(41.7)
110
(45.8)
Depression Score
0.2117
High
17
(23.6)
41
(17.1)
Low
55
(76.4)
199
(82.9)
Hypertension
Yes
22
(37.9)
68
(34.0)
0.5802
No
36
(62.1)
132
(66.0)
Continued on next page

53

Table 3.5. (Continued)
Diabetes
Yes
No
Heart Disease
Yes
No
Infant Gender
Female
Male
*Plus-minus values are means ±SD.
SGA= small for gestational age.

a.

21
37

(36.2)
(63.8)

65
136

(32.3)
(67.6)

0.5816

10
49

(16.9)
(83.1)

28
170

(14.1)
(85.9)

0.5938

38
26

(59.4)
(40.6)

107
114

(48.4)
(51.6)

0.1225

some cell numbers do not sum up to 345. b significant p values are in bold.
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Table 3.6. Adjusted effect of folate treatment on small for gestational age among trial
population (n=312)
Variables
Relative Risk
95% C.I
Treatment
High dose

0.69

0.46- 1.03

Low dose

ref

-

Black

1.51

0.99- 2.31

Other

1.01

0.54- 1.90

White

ref

-

High

2.51

1.50-4.23

Moderate

1.92

1.17- 3.14

Low

ref

-

Race

Cotinine group

Adjusted for cotinine group trajectory and race. C.I= confidence interval; Estimates in bold are significant at pvalue <0.05.
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CHAPTER FOUR:

MANUSCRIPT 3: EFFICACY OF HIGHER-STRENGTH FOLIC ACID ON FETAL BRAIN GROWTH AND
DEVELOPMENT AMONG WOMEN WHO SMOKED DURING PREGNANCY

ABSTRACT
The role of folic acid supplementation in fetal head growth among women of
reproductive age is well documented in observational studies. However, research on the effect
of folate supplementation among high-risk subgroups, such as women who smoke during
pregnancy, is minimal. Furthermore, no experimental study has been conducted to examine
this relationship. In this study, we investigated the efficacy of high strength folic acid
supplementation vs. standard dose on increasing prenatal fetal brain growth, measured by
head circumference, brain weight, and brain-body ratio.
A randomized, double-blind, controlled clinical trial involving 345 smoking pregnant
mothers was conducted. Participants were recruited between 2010-2015 at the Genesis Clinic
Tampa, a community health center affiliated with the Department of Obstetrics and
Gynecology of the University of South Florida (USF). Those who met the eligibility criteria were
randomly assigned in a 1:1 ratio to receive either 0.8mg/day of folic acid (standard of care) or
4mg/day of folic acid (higher-strength). They were also enrolled in a smoking cessation
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program. The two-level linear growth model, a type of multilevel modeling, was used for
assessing treatment effect and factors that predict intrauterine increase in head circumference
over time. Multiple linear regression analyses were conducted to estimate the effect of higherstrength folic acid on head circumference at birth, fetal brain weight, and fetal brain-to-body
ratios (BBR).
Mothers who received higher strength dose of folate had infants with a 1.18mm larger
mean head circumference compared to infants of mothers who received the standard folate,
but this difference was subtle and not statistically significant (P = 0.2762). High-dose folate also
had no significant effect on head circumference and brain weight in our trial sample. However,
the BBR of infants of mothers who received high-dose treatment was 0.33 percentage-point
lower than for infants of mothers who received the standard dose of folate (P =0.044).
In conclusion, smokers in pregnancy may benefit from folate supplementation in
reducing the risk of having infants with impaired brain-body proportionality. A decrease in the
proportion of infants with impaired BBR might contribute to a reduction in morbidity and
health care cost associated with future neurocognitive disorders.

INTRODUCTION
A relatively large literature addresses the role of maternal smoking on fetal
development20,65 67,68 and the developing brain is possibly the most sensitive organ to nicotine
exposure.102 Nicotine readily crosses the placenta into the fetal serum and brain,103 and has
been found to be neurotoxic.104 Maternal tobacco exposure is associated with reduced head
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circumference,20,21,105,106 altered indicators of infant body proportionality such as brain-to-body
weight ratio (BBR),107 and neurocognitive developmental problems in the offspring.108-110
Though smoking cessation before mid-pregnancy may result in complete elimination of
smoking-related deficits in infant head circumference and BBR,105,107 many mothers find it
difficult to quit; thus, exposing their unborn babies to the harmful effect of tobacco.
One likely mechanism of action of maternal smoking on adverse fetal outcomes is
through a reduction in the concentration and activity of maternal folic acid reserve. 11,15,28
Smokers are more likely to consume fewer folate-rich diets and have impaired folate
metabolism.13,28-30 Low maternal folate levels reduce the bioavailability of folate to the
developing fetus, resulting in impaired growth. 111 Previous studies provide some evidence that
prenatal folate deficiency might have an adverse effect on global fetal brain growth,112
however, folate supplementation in early pregnancy may increase head circumference at
birth112 and reduce neurodevelopmental disorders in offspring. 108, 113
The role of folic acid supplementation and folate concentrations in fetal head growth
among women of reproductive age is well documented. 112,114 However, research on the effect
of folate supplementation among a high-risk subgroup such as women who smoke during
pregnancy is minimal. Furthermore, no experimental study has been conducted to examine this
relationship. In this study, we investigated the efficacy of high strength folic acid vs. standard
dose folic acid on increasing prenatal brain growth. Specifically, the outcomes were head
circumference, brain weight and brain-body ratio, a measure of brain-body proportionality
derived from head circumference. Head circumference is a non-invasive proxy for fetal brain
growth and development,114 and is closely correlated to brain volume. 115,116 In this study, we
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hypothesized that among smoking mothers enrolled in a smoking cessation program, higher
strength folic acid treatment is associated with increased fetal brain growth.

METHODS

Trial Population and Design
This was a randomized, double-blind, controlled clinical trial in which 345 smoking
pregnant mothers underwent randomization. Eligible participants were randomly assigned in a
1:1 ratio to receive either 0.8mg/day of folic acid (standard of care) or 4mg/day of folic acid
(higher-strength). The folic acid tablets had exactly the same color, shape, size, and were
packed in identical coded bottles. The code was the only distinguishable feature which was
used to determine whether the bottle contained a 0.8 mg or 4 mg folic acid tablet. This code
was concealed with patient ID labels. The physicians, ultrasound technicians, laboratory staff,
study investigators and study participants were masked to the treatment groups.
Randomization was performed by a biostatistician through a computer-generated
randomization schedule, using a permuted block design with a block size of 12. This type of
design was chosen to allow balance in the number of participants in each group at the end of
the clinical trial. The coded randomization schedule was properly stored in a sealed envelope
within a locked file cabinet. In addition to the intervention, both study arms received
preparations of multi-vitamins that did not contain folic acid and were enrolled in the smoking
cessation program at the study site.
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Participants were recruited between 2010-2015 at the Genesis Clinic Tampa, a
community health center affiliated with the Department of Obstetrics and Gynecology of the
University of South Florida (USF). Almost all the pregnant women who receive antenatal care at
the Genesis Clinic deliver their babies at the USF Department of Obstetrics and Gynecology at
Tampa General Hospital because of reduced cost of delivery for low-income women at this
location. This made it easier to track patients and retrieve their birth data, thereby reducing
loss to follow-up.
Women were eligible for participation in the study if they were (1) current smokers (2)
ages 18-44 years; (3) less than 21 weeks gestation as confirmed by last menstrual period; and
(4) residents of Tampa, Florida, or a surrounding area, to facilitate follow-up and reduce
attrition rate. To identify pregnant women who smoked at baseline, screening for cotinine- a
biological marker for nicotine was done using saliva. Women with detectable cotinine levels of
1 or more were confirmed eligible for the study. Participants were excluded if there was
evidence of an indication for chronic blood transfusion and generalized seizure disorder treated
with anti-convulsant medication. Women receiving chronic blood transfusion may have
inaccurate measures of folate RBC levels, due to transfused red blood cells (RBC). Additionally,
patients treated with anticonvulsants may have folic acid deficiency as side effects of the
medication.37 Table A2.4 in Appendices shows the schedule of data collection, instruments, and
procedures used in this trial. Fetal ultrasounds, study questionnaires, and salivary cotinine
laboratory assessments were completed during the three study visits. At delivery, cotinine level
was further evaluated, and fetal body measurements were taken.
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Written informed consent was obtained from all the participating women before trialrelated procedures were initiated at screening and enrollment. Informed consent was available
in both English and Spanish. The study was funded by the James and Esther King Biomedical
Research Program, Florida Department of Health (grant numbers 4KB03 and 1KG14-33987). The
trial protocol was approved by the Institutional Review Board of the University of South Florida.

Smoking Cessation Program
All women enrolled in the trial signed a contract stating they agreed to commit to
quitting smoking, and attended at least one smoking cessation session at the study site for
smoking mothers or called the Florida Quit Line. The counseling sessions focused on the
following; (1) receipt of self-help materials and how to make a quit attempt, (2) effects of
secondhand smoke, partners who smoke and tips on how to establish smoke-free homes and
cars, (3) stress management and benefits of not smoking, and (4) prevention of smoking
relapse. Women who persistently tested positive to salivary cotinine were referred by study
personnel to Florida’s QuitLine, a toll-free telephone-based tobacco use cessation service.
Additionally, all women were linked to community smoking cessation services such as the
Hillsborough County Healthy Start program, a free, voluntary and intensive smoking cessation
program.

End-Point Measures
The outcomes were prenatal fetal brain growth defined as (1) rates of growth in intrauterine
ultrasound measure of head circumference (growth velocity); and (2) three different measures
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of cumulative head circumference growth (head circumference at birth, fetal brain weight, and
fetal brain-to-body ratios (BBR)). The serial ultrasound measurements of head circumference
(HC) were taken during the three expected study visits using standardized ultrasound
procedures. Some women had more than three ultrasound procedures, due to request from
healthcare providers, while some had fewer procedures due to no-show or loss to follow-up.
Intrauterine HC was measured to the nearest millimeter on a transverse view of the fetal head
in a plane showing both thalami and the third ventricle. The second outcome, head
circumference at birth was measured to the nearest centimeter using a measuring tape. The
third outcome, fetal estimated brain weight was derived from the National Institute of
Neurological and Communicative Disorders and Stroke’s Collaborative Perinatal Project and was
calculated using this formula: [0.037 × head circumference (cm) 2.57].117 The last outcome, the
brain-to-body ratio (BBR) was defined as the percentage of the infant’s birth weight that is
estimated to occupy the brain is a function of the head circumference. The BBR is calculated as
100 × the ratio of the infant’s estimated brain weight to its birth weight and is expressed as BBR
= 100 × [0.037 × head circumference (cm) 2.57] /birth weight (g). A high BBR indicates a higher
percentage of birth weight residing in the brain, while a lower BBR suggests a lower fraction of
birth weight residing in the brain.107 The typical values for healthy infants have been estimated
to be 9-10%.107 Furthermore, higher BBR indicates larger brain weight for a given head
circumference and is associated with small-for-gestational-age infants.116
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Covariates
Based on prior knowledge, a number of maternal and infant characteristics were
considered as potential confounding factors due to their demonstrated association with fetal
brain development. These include sociodemographic factors (such as maternal age, race,
marital status, and insurance status), lifestyle factors (such as cotinine level, alcohol
consumption, dietary folate and maternal body mass index (BMI)), and perinatal factors such
maternal depression, stress, gestational age and maternal chronic diseases such as
hypertension and diabetes. Gestational age (GA) at delivery, a measure of duration of the
pregnancy in weeks, was based on dating ultrasound at first prenatal visit and the date of
delivery of the baby.
Sociodemographic and lifestyle factors were extracted from participants’ medical
records, specifically the American College of Obstetrics and Gynecology (ACOG) form. This form
is routinely used at the study site to document mothers’ information such as demographic,
obstetric and gynecologic history, and results of physical and laboratory examinations.
Race/ethnicity was categorized into three groups: non-Hispanic black (black), non-Hispanic
white (white), and other (includes Hispanic). Age was defined as both continuous and
categorical variable (grouped as 18-14, 25-34 and ≥35 years). Marital status was dichotomized
as either married or unmarried, the latter included divorced, separated and unknown marital
status. Insurance (health insurance) was categorized as private or public/uninsured. BMI was
calculated using maternal self-reported pre-pregnancy weight and height measured at
enrollment. BMI was calculated as weight (kg)/ height (m)2 and categorized into normal
(<25.0kg/m2), overweight (25.0–29.9kg/m2) and obese (≥30.0kg/m2). Although 5 women had
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BMI below 18.5 (underweight), they were included in the normal BMI group due to limited
sample. Dietary folate was assessed using a proxy, maternal red blood cell (RBC) folate
concentration at study baseline. RBC folate was measured using enzyme-linked immunosorbent
assay (ELISA). This was the preferred folate biomarker because of its advantages of long-term
stability and reduced susceptibility to sudden changes in diet.19 Folate level was defined as a
continuous variable.
Depression was assessed using the Edinburgh Postnatal Depression Scale (EPSD). This is
a validated tool for assessing ante-natal and post-natal depressive symptoms depression
measurement.44 Mothers who score above 12 or 13 on the scale are likely to be suffering from
depression.45 We dichotomized this variable as high and low, using a cut-off point of 12. Stress
was measured using the Perceived Stress Scale (PSS-14) scale, which is a validated tool for
comparisons between people in study samples.46 As a result, women who had a score equal to
or greater than the mean stress score for the sample were classified as having high-stress
levels, while those who had a score below the mean were classified as having low-stress levels.
Cotinine was measured by a test of maternal saliva for the presence of cotinine with the
use of a rapid semi-quantitative screening test called NicAlert (Jant Pharmacal Corporation,
Encino, CA). Salivary cotinine analysis is the most sensitive and specific of the three types of
cotinine measures.78 This method has a sensitivity of 99% and specificity of 82%. The cotinine
test strip displays seven levels (0-6); with each level representing a range of cotinine
concentrations. Based on the manufacturer’s guidelines, individuals with a reading of at least a
level 1 result are considered smokers. With increasing level of cotinine, cotinine concentration
increases. Cotinine level was treated as a continuous variable in our analysis.
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Statistical Analysis
The parent grant was designed with a planned sample of 400 women with 200 in each
intervention group. This was the estimated number from a sample size calculation conducted to
evaluate the efficacy of higher-strength folic acid in combination with smoking cessation
programs in preventing a reduction in the trial’s primary outcome; small for gestational age.
However, a total of 100 (50 smoking mothers in each treatment arm) was the estimated sample
size required to determine whether higher-strength folic acid will improve fetal brain growth.
This was based on the following assumptions: a type 1 error rate of 5%, power of 80%, a mean
biparietal diameter (BPD) of 95.0mm (SD±2.5) at term for infants of non-smokers based on BPD
reference values at the study site, and a 50% reduction in the rate of loss of fetal brain
growth.105 A total of 345 women were enrolled, indicating sufficient power to find a treatment
effect on fetal brain growth if one exists.
Descriptive statistics were conducted for all variables examined. We assessed the
differences in the baseline sociodemographic, lifestyle and health-related characteristics of
study participants by their treatment groups. Means of continuous data were compared using
independent t-tests or ANOVA, while categorical variables were compared using the chi-square
test. Using the intention-to-treat population, birth outcomes for all study participants were
described using frequencies and percentages. All primary analyses were conducted on a
modified intention-to-treat basis and included participants who completed the trial with an
observed endpoint, irrespective of compliance to protocol. These analyses excluded all
pregnancies that ended in a fetal loss (abortions, fetal demise, still births, miscarriages),
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congenital anomalies or multiple births. Growth potentials for fetuses with congenital
anomalies or those from multiple gestation may not be comparable to singleton pregnancies
without abnormalities. Twenty-six cases (n=26) were excluded, therefore leaving the total
participants eligible to be included in the analyses as 319. For the brain growth velocity
analysis, data were available for only 258 (80.9%) subjects who had at least one measurement
of HC in-utero. For the cumulative growth analyses, data were obtainable for 215 subjects
(67.4%) who had endpoint data on HC recorded at birth.
Since there were four repeated measures of cotinine level from participants during the
trial, the decision was made to identify the unique paths of cotinine levels throughout the
pregnancy. Group-based latent class trajectory model, a semiparametric method, used to
discover patterns, was utilized. This approach offers a data-driven method to identify distinct
individual patterns of a variable of interest and the corresponding probability of falling into
each pattern, also known as the posterior probability.86 Trajectory analyses were conducted,
and participants were then classified into groups based on their highest posterior probability.
The fit of five models, with two to six subgroups, were compared by applying all linear
terms and quadratic terms (Table A2.5 in Appendices). Model 4 had the highest Bayesian
information criterion (BIC), but the log Bayes factor approximation (2(∆BIC)) comparing the
three-group model to the four-group model was low (4.4 and 3.8 for linear and quadratic terms
respectively). According to the criteria for the log Bayes factor approximation, 87 there is no
strong evidence against the null three-group model when comparing the two models, so the
three-group model has a better fit. Therefore, it appears that three groups is the optimal
number of latent cotinine subgroups. We also determined the polynomial degree for each
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trajectory in the three-group model by investigating every permutation of both linear and
quadratic terms (Table A2.6 in Appendices). We sorted from the best to worst model, based on
BIC. Consequently, model one was chosen as the best combination of polynomial degrees for
the three-group cotinine model. The discriminated cotinine group identified was included in our
analyses as a group variable representing cotinine trajectory. All statistical tests were two-sided
with an alpha level set at p<0.05 and conducted in SAS 9.4.

Fetal Brain Growth Trajectory
The primary outcome was the rate of intra-uterine growth rate in HC from the beginning
of the second trimester of pregnancy until delivery. The two-level linear growth model, a type
of multilevel modeling, was used for assessing treatment effect and factors that predict
intrauterine growth in head circumference over time. Multilevel modeling is an analytic
procedure developed to account for the dependency in observations when data have a nested,
multilevel structure, such as days (Level 1) nested within-person (Level 2). In this study, the
Level 1 relationship between gestational age and fetal HC was modeled individually for each
participant, and the average relationship, across participants, was reported. Level 2 variables
were then sequentially included in the model to account for differences between babies in the
average fetal brain growth. These subject level covariates comprised maternal BMI, cotinine
levels, and fetal gender. Treatment, the primary exposure, was also included. The level 1
variable, repeated measures of gestational age was centered because it does not have a
meaningful value of zero (i.e., at a gestational age of zero, fetal brain size or head
circumference cannot be measured). This variable was centered at 13 weeks because this
67

period signifies the beginning of the second trimester of gestation. Furthermore, no ultrasound
measurements of HC were recorded before 13 weeks’ gestation. None of the Level 2 variables
were centered because they had a meaningful value at zero.
Growth velocity curves (growth trajectories) were plotted and compared between
mothers on higher-strength folic acid versus those on the standard of care. The treatment
effect, which is the difference between the two groups, were determined from the multilevel
models. In the first model, the unconditional growth of HC was modeled as a function of
gestational age. The intercept and slopes were fit as random effects, which varied across
fetuses. Estimation methods were assessed in this model using the unstructured, compound
symmetry, autoregressive (AR (1)), autoregressive heterogeneous and the VC forms of
covariance matrices. Since the same fixed effects were included in all models, a log-likelihood
ratio test was used to compare models. Table A2.9 in Appendices shows the comparisons
between these models. The model with an unstructured covariance matrix had the best fit and
was utilized in modeling.
Variables that were either associated with folate treatment or head circumference at
birth in our bivariate analysis or the literature were included in the model building process.
Based on the log-likelihood ratio, only three of the likely confounding variables improved the
model fit namely cotinine group, gender and BMI. In addition to the unconditional model
(model 1), results from the following models were also reported: 2) model 1+ treatment; 3)
model 2 + cotinine group trajectory; 3) model 3 + fetal gender; and 5) model 4 + maternal BMI.
Model 5 had the best fit. Thus, treatment effect and other fixed and random effects parameter
estimates were reported from this model.
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Cumulative Growth in Fetal Brain
These analyses examined the effect of the intervention on head circumference at birth,
fetal brain weight, and fetal brain-to-body ratios (BBR). These endpoints which are based on
data collected at delivery were treated as continuous variables. Since these indices had
approximately normal distributions (Table A2.10, Fig A2.2-2.4 in Appendices). Independent ttests and ANOVA were used to compare the mean values of outcomes between the trial
treatment groups and participants’ characteristics. Multiple linear regression analyses were
conducted separately for all the outcomes. To account for potential confounders, we controlled
for race because of the imbalance across treatment groups after randomization. Cotinine group
trajectory was also included in the model to account for possible changes in cotinine levels
during the course of pregnancy. Mean differences in the outcomes and their corresponding
standard errors were reported.

RESULTS

Study Participants
Figure 4.1 describes the enrollment and follow-up of the participants. A total of 345
smoking pregnant women were enrolled in the trial; 171 women were randomly assigned to
the high-dose folate and 174 to standard dose folate. Of these women, 258 (74.8%) had at least
one ultrasound measurement of HC and 215 (62.3%) had outcome data on HC at delivery.
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These numbers, 258 and 215, represent the number of participants included in the modified
intention-to-treat analysis of brain growth trajectory and cumulative brain growth respectively.
In Table 4.1, we present the sociodemographic, lifestyle and health-related
characteristics of study participants by folate dose treatment received. The baseline
characteristics of the participants in the two groups were well matched with the exception of
race. Women of ‘other’ race including Hispanic women were more likely to be assigned to the
standard of care. The average (±SD) age of participants was 26.7 (±5.6) years. The mean
gestational age at enrollment and the mean baseline folate concentration were 12.3 (±3.9)
weeks and 718.5 (±187.0) ng/ml respectively. The trial population was predominantly made up
of women who were single/divorced (90.1%) and without insurance or on public insurance
plans (95.1%). Approximately two-thirds of the population was either overweight or obese
(67.7%), and about one-third had hypertension (34.3%) or diabetes (32.7%).
Table 4.2 shows a description of the overall birth outcomes for all study participants.
The total number of live births was 312 (90.4%). In all our analyses, we excluded 26 participants
(7.5%) for the following reasons: pregnancies that ended with induced abortion/miscarriage
(n=12), congenital anomaly (n=2), fetal demise (n=5), stillborn (n=3), or multiple gestations
(n=4). There were no distinct differences in the rate of excluded birth outcomes and live births
by treatment group.
Figure 4.2 illustrates the longitudinally-derived cotinine trajectories for trial participants.
We discriminated three distinct groups of maternal cotinine velocities; one with a consistently
high level of cotinine, another with a low level and the third group with moderate cotinine level
but a marked decline towards the end of gestation. Approximately 18.9%, 48.3% and 32.8% of
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the study participants were classified respectively into the groups stated above. At the end of
the study, only 3.0% of the women with cotinine data at delivery (n=8) had stopped smoking
(cotinine level of zero).

Fetal Brain Growth Trajectory
Figure 4.3 displays a spaghetti plot of brain growth for all study participants irrespective
of their treatment allocation. Overall, a linear trend in growth was observed, with a slight
reduction in growth rate starting from about 33 weeks of gestational age. Figures A2.5. and
A2.6 in Appendices show spaghetti plots of brain growth for the high-dose folate and standarddose folate groups respectively. In Figure 4.4, we illustrate the fetal brain growth trajectories by
treatment. There were no noticeable differences between fetal growths in head circumference
for either treatment group.
In Table 4.3, we present the results of multilevel linear growth models for the
longitudinally measured fetal head circumference using the modified intention-to-treat
population. In the adjusted model, the mean head circumference at 13 weeks (due to centering
at 13 weeks) for all fetuses was about 109.2mm (P <0.001). This time corresponds to the
beginning of the second trimester of pregnancy. The average rate of growth in head
circumference per week starting at the onset of the second trimester of gestation was 9.66mm,
and this was also statistically significant (P <0.001). Even though infants of individuals who
received higher strength dose of folate had a 1.18mm larger head circumference than the
infants of those who received the standard folate, this difference was subtle and not
statistically significant (P = 0.2762). The between individual variance in the outcome was
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67.7mm (P <0.001), indicating that the initial head circumference at GA of 13 weeks across
fetuses was significantly different. This difference was mainly explained by differences in
maternal BMI status and the gender of the fetus (Table 3). The within-individual variance was
70.1mm and statistically significant (p<0.001); indicating significant variability in brain growth
over time across children. Maternal cotinine group level accounted mainly for this difference.
However, cotinine group trajectory had no significant effect on the rate of brain growth in this
study. Fetuses who had a smaller HC at the beginning of the second trimester had a significantly
faster rate of growth than those who had a larger HC (τ10= -6.00). Compared to male fetuses,
their female counterparts had a 3.2mm slower growth rate in head circumference (P =0.003)

Cumulative Growth in Fetal Brain
The mean (±SD) head circumference of babies at birth was 33.8cm (±2.0), and there was
no statistically significant difference by treatment (P =0.1519) (Table 4.4). Differences in head
circumference were present by cotinine group trajectory, maternal illicit drug use and marital
status. Married women, mothers in the low cotinine group and those who did not abuse drugs
while pregnant had babies with significantly larger HC (P ≤0.05). In Table 4.5, we present the
results from the multivariable linear regression of the effect of treatment on HC at birth. Highdose folate increased HC at birth by 0.34cm among smokers in pregnancy but this effect was
not statistically significant (P =0.1844). Compared to mothers with low cotinine levels, mothers
with moderate or high cotinine levels had babies with approximately 1.2cm lower head
circumference at birth (P <0.0005). Infants of black mothers had a 0.72cm lower head
circumference at birth than infants of their white counterparts (P =0.0132).
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Table 4.6 presents the characteristics of the trial population by mean brain weight and
brain-body ratios. There were significant differences in the mean brain weight of babies of
smokers in pregnancy by marital status, illicit drug use and cotinine group (P <0.001). Another
outcome, the brain-body ratio (BBR), also differed significantly by cotinine group trajectory. In
this instance, there was an inverse association when compared to HC and brain weight. With
increasing cotinine group level, BBR increased significantly (P <0.001). BBR also differed
significantly by treatment group. Mothers who received higher strength folate had lower BBR
than the mother who received the standard of care (P =0.0043)
In Table 4.7, the results of the multivariable regression on the effect of treatment on
fetal brain weight are presented. High-dose folate had no significant effect on brain weight in
our trial sample of smoking mothers (mean difference 6.90, SE= 5.85, P =0.2396). Compared to
infants of mothers in the low cotinine groups, infants of mothers in the high or moderate
cotinine levels had approximately 30g lower brain weight (P <0.001). Infants of black mothers
also had smaller brain weight at birth than infants of white mothers (P =0.013).
Fetal brain-body ratio for the infants of the study participants ranged from 7.4%-13.9%.
Table 4.8 shows the effect of folate treatment on fetal brain-body ratio after controlling for
potential confounders. The BBR of infants of mothers who received high dose treatment was
0.33 percentage-point lower than for infants of mothers who received the standard dose of
folate (P =0.044). Unlike other measures of cumulative brain growth, high cotinine group and
black race were associated with higher BBR. Compared to women who had low cotinine level,
mothers with high cotinine levels had 0.93% higher BBR (P <0.001). Infants of black mothers
had approximately 0.5% higher BBR than infants of white mothers (P =0.0075).
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DISCUSSION
This randomized clinical trial compared the efficacy of a combination of higher strength
folic acid supplementation and enrollment in smoking cessation program versus standard of
care folic acid dose in conjunction with enrollment in smoking cessation program on increasing
prenatal brain growth among smokers in pregnancy. Higher strength folic acid supplementation
in combination with smoking cessation had no effect on intrauterine head growth from the
beginning of the second trimester of gestation through delivery. We observed a significant
effect of maternal folic acid treatment on brain-to-body ratio, but no effects on head
circumference and brain weight at birth. The absence of a difference in the rate of intrauterine
head growth and head circumference at birth by trial groups might be explained by the
initiation period of folate supplementation. The mean gestational age at study enrollment and
commencement of supplementation was 12.3 weeks, approximately the end of the first
trimester of pregnancy. Previous studies have reported that rapid development of the fetal
brain occurs during the early stage of gestation, with neurogenesis in most cortical and
subcortical structures of the brain occurring between 5 and 25 weeks of gestation.118 In the
current study, a high proportion of the participants were enrolled after the first trimester, thus,
there is a possibility that we missed the opportunity to demonstrate a treatment effect if it
indeed exists.
The infant of women on higher-strength dose experienced a 0.33%-point reduction in
brain-body ratio compared to their counterparts on the standard treatment (P =0.044). This
may indicate that folate does not favor fetal brain over fetal body growth, particularly if
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supplementation is not commenced early in pregnancy when rapid brain growth occurs. A high
BBR signifies a larger brain weight for a given head circumference, and this is commonly
observed in small-for-gestational-age infants116 and intrauterine growth restriction (IUGR).120
Therefore, a decrease in BBR found in this trial correlates with a lower risk of SGA birth among
the high folate dose group. Harel and colleagues120 reported that higher the brain-body ratio
was associated with more severe the intrauterine growth restriction (IUGR) process and a
greater the risk for the fetal brain to be affected.120 The observed reduction in BBR in the
current might have important consequences for families and the health care systems by
reducing the burden of caring for individuals associated sub-optimal neurodevelopmental
problems. Because a relatively large segment of women smoke during pregnancy,3, 33, 34, 119 a
0.33%-point reduction in brain-to-body ratio will translate to preventing a large number of
probable cases of infants with neurocognitive and behavioral problems.
Significant relationships between cotinine trajectory group and the cumulative
measures of brain growth were also observed. A dose-response relationship was observed for
all outcomes. Higher cotinine level was associated with worse outcomes i.e. lower HC at birth,
reduced brain weight and higher BBR. Lindley et al107 found similar effects of smoking on HC
and BBR. In their observational study, nonsmokers were compared with mothers who stopped
smoking by 32 weeks of gestation, light smokers who continued to smoke, and heavy smokers
who continued to smoke during pregnancy. A dose-response gradient was observed with these
self-reported smoking levels. It is well documented that maternal smoking affects fetal brain
development and results in neurocognitive issues such as deficits in IQ in the offspring.118, 125
Because infants born to mothers with lower levels of cotinine had a reduced risk of adverse
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fetal brain outcome than those born to mothers with higher levels, being able to get women to
reduce smoking or maintain minimal smoking if not completely quit will have significant
implication for reducing the incidence of neurodevelopmental problems. It is noteworthy that
despite being enrolled in smoking cessation programs, only 3% of the study participants quit
smoking. Other findings in this trial are the increased risk of adverse cumulative brain growth
outcomes among blacks. Our study confirms previous reports that black mothers compared to
white mothers have worse birth outcomes including infants with lower birth weight and smaller
head circumference.89, 98
There are some limitations to note regarding the present study. We lost a relatively high
proportion of the participants to follow-up. For instance, in our multilevel modeling, we had
data on only 82.7% (n= 258) of the 319 women eligible to be included in the modified intentionto-treat analysis. There were no significant differences in demographic characteristics between
the participants lost to follow-up and those who remained in the study. Therefore, we do not
expect loss to follow-up to bias our result in a significant way. We did not directly assess or
control for the effect of diet, a possible confounder in this study. However, there is a reduced
likelihood in dietary differences by treatment groups because of randomization. Furthermore,
the baseline comparison of RBC folate, a proxy for long-term folate diet supports this claim. As
with most clinical trials, the generalizability of our findings to an external population is an issue.
Voluntary participants in studies are usually different from nonparticipants. In this instance, the
participants may be more health conscious and, therefore, our findings could be biased towards
the null. In the baseline assessment of RBC folate in this study, it was observed that only 2
women had folate deficiency as defined by the laboratory’s guideline of less than 280 ng/ml.
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The study sample was made up of low income women with a high proportion of minority,
further limiting the generalizability of the findings.
There are numerous strengths of this trial. The use of double-blind, randomized clinical
trial allows for causal inference. We conducted modified intention-to-treat analysis, so our
findings will closely represent the effectiveness of higher strength folic acid in improving
prenatal brain growth under real-world conditions. To our knowledge, this is the first
randomized control trial to report on the efficacy of high strength folic acid in combination with
enrollment in smoking cessation program in preventing adverse fetal brain outcomes among
smokers in pregnancy.
The vulnerability of the developing fetal brain is dependent on whether an exposure or
its active metabolite(s) reaches the developing nervous system and the period of exposure.118 In
our trial, we cannot say with certainty that folate supplementation was commenced at the
critical period of brain growth and that folate reached the brain at the dose at which we
supplemented. Future experimental studies should investigate the role of early folic acid
supplementation among smokers starting from before conception until delivery. This method
may help in identification of the critical period of development associated with maximum
folate-associated brain growth. It is also crucial to understand the differences between the
effects of folic acid supplementation versus blood folate concentrations on fetal brain. Blood
folate levels including RBC and serum folate are better proxies for the assessment of folate
status.122 These biomarkers are recommended for assessing folate bioavailability for optimal
neural cells growth and development.
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In conclusion, we demonstrated a substantial reduction in brain-to-body-ratio with the
use of higher strength folate initiated during early-mid pregnancy. However, no treatment
effects were found on intrauterine brain growth rate, HC at birth and brain weight. The
significant findings show that smokers in pregnancy may benefit from folate supplementation
in reducing the risk of having infants with impaired brain-body proportionality. A decrease in
the proportion of infants with impaired BBR might contribute to a reduction in morbidity and
health care cost associated with future neurocognitive disorders.
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345 women underwent randomization

Baseline: 171 were
assigned to receive 4mg
of folic acid once daily

Baseline: 174 were
assigned to receive
0.8mg of folic acid once
daily

19 Lost to follow-up
7 Fetal loss

18 Lost to follow
7 Fetal loss

Visit 2: 149 participants
attended follow-up visit

Visit 2: 145 participants
attended follow-up visit
8 Lost to follow-up

4 Lost to follow- up
Visit 3: 137 participants
attended follow-up visit

Visit 3: 145 participants
attended follow-up visit

11 Lost to follow-up
or delivered outside
of center, 4 Fetal
loss, 1 Congenital
anomaly, 2 Multiple
gestation

13 Lost to follow-up
or delivered outside
of center, 2 Fetal
loss, 1 Congenital
anomaly, 2 Multiple
gestation
128 Were included in the
modified intention-to-treat
analysis of brain growth
trajectory (at least one
intrauterine measure of HC)

130 Were included in the
modified intention-to-treat
analysis of brain growth
trajectory (at least one
intrauterine measure of HC)

105 Completed study with outcome data
on head circumference and were
included in the modified intention-totreat analysis of cumulative growth

110 Completed study with outcome data
on head circumference and were
included in the modified intention-totreat analysis of cumulative growth

Figure 4.1. Enrollment, randomization, and follow-up of participants
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Table 4.1. Baseline socio-demographic, lifestyle and health-related characteristics of all
randomized study participants by folate treatment (N=345).
Variables
High-Dose
Standard Dose P-valueb
Folate (N=171) Folate (N=174)
a
N
(%)
Count (%)
Count (%)
Age in years
26.7±5.6
26.4±5.1
27.3±5.8
0.1035
Gestational Age
12.3±3.9
12.4±3.9
12.2±3.9
0.5721
Baseline Cotinine
2.9±1.4
3.0±1.5
2.9±1.4
0.3535
Baseline Folate
718.5±187.0 731.3±180.9
706.0±192.3
0.2100
Race
0.0274
White
148 (42.9) 78
(45.6) 70
(40.2)
Black
140 (40.6) 74
(43.3) 66
(37.9)
Other
47
(16.5) 19
(11.4) 38
(21.8)
Marital Status
0.255
Married
34 (9.8)
20
(11.7) 14
(8.05)
Single/ Divorced
311 (90.1) 151
(88.3) 160
(91.9)
Spanish Speaking
Yes
21
(6.1)
8
(4.7)
13
(7.5)
0.2780
No
324 (93.9) 163
(95.3) 161
(92.5)
Insurance
0.4336
Public/None
328 (95.1) 161
(94.1) 167
(96.0)
Private
17
(4.9)
10
(5.9)
7
(4.0)
BMI
Not overweight
111 (32.4) 53
(31.0) 58
(33.7) 0.1239
Overweight
85
(24.8) 36
(21.0) 49
(28.5)
Obese
147 (42.9) 82
(47.9) 65
(37.7)
Alcohol Use
Yes
30
(9.5)
18
(11.2) 12
(7.6)
0.2727
No
287 (90.5) 142
(88.7) 145
(92.4)
Illicit Drug Use
Yes
94
(31.0) 50
(32.9) 44
(29.1) 0.4798
No
209 (69.0) 102
(67.1) 107
(70.9)
Stress Score
High
191 (55.4) 95
(55.6) 96
(55.2) 0.9498
Low
154 (44.6) 76
(44.4) 78
(44.8)
Depression Score
High
63
(18.3) 31
(18.1) 32
(18.4) 0.9498
Low
282 (81.7) 140
(81.9) 142
(81.6)
Hypertension
Yes
113 (34.3) 54
(33.1) 59
(35.5) 0.6449
No
216 (65.7) 109
(66.9) 107
(64.5)
Continued on next page
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Table 4.1. (Continued)
Diabetes
Yes
No
Heart Disease
Yes
No

108
222

(32.7)
(67.3)

52
111

(31.9)
(68.1)

56
111

(33.5)
(66.5)

0.7522

42
286

(12.8)
(87.2)

22
141

(13.5)
(86.5)

20
145

(12.1)
(87.9)

0.7093

*Plus-minus values are means ±SD. a. some cell numbers do not sum up to 345 due to missing data. b significant p
values are in bold.
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Table 4.2. Birth Outcomes for Study Participants in the Intention-to-Treat Population (N=345)
Event
High-Dose Folate (N=
Standard Dose Folate (N=
Pvalue
171)

174)

no. of participants (%)
Live birth

152 (88.9)

160 (91.9)

0.0798

Induced

6 (3.5)

6 (3.4)

0.4272

Congenital anomaly

1 (0.6)

1 (0.6)

0.9755

Fetal demise

3(1.7)

2 (1.1)

1.0000

Still born

2 (1.2)

1 (0.6)

0.6830

Multiple gestation

2 (1.2)

2 (1.1)

0.6206

*Complete loss to follow-up

5 (2.9)

2 (1.1)

1.0000

abortion/miscarriage

*Indicates delivery records that were not available or retrievable.
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Figure 4.2. Longitudinal-Derived Cotinine Trajectories in the Modified Intention-to-Treat
Population (n=319)
Each straight line reflects an individual cotinine trajectory: 1-low level; 2-moderate level; and 3high level.
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Head circumference (mm)
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Figure 4.3. Individual Growth Velocity Trajectories in Fetal Head Circumference from the
Beginning of Second Trimester till Delivery (N=258)
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Figure 4.4. Trajectories in Head Circumference of Fetuses of Participants by Treatment from
the Beginning of Second Trimester till Delivery (N=258)
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Table 4.3. Multilevel linear growth models for the effect of treatment on growth in fetal head
circumference (N=258)
Parameter
Estimate
Model 1
Model 2
Model 3
Model 4
Model 5
Fixed effects
Intercept (γ00)
108.16
107.72
107.67
108.19
109.20
GA a (γ01)

9.70

9.70

9.70

9.69

9.66

High Dose

1.02

0.98

1.38

1.18

Standard Dose

-

-

-

-

Low

0.94

0.90

0.78

Moderate

1.30

1.73

1.84

High

-3.10

-3.21

Treatment (γ10)

Group

Gender
Female
Male
BMI
Not Overweight
Overweight
Obese
Deviance (-2LL)

-1.61
-0.75
8188.6

8185.7

a

8180.4
b

7775.2

7736.6

Note. Centered variable (centering done using the value 13 weeks); Cotinine at delivery. Estimates in bold are
significant at p-value <0.05. C Model 1 was used as baseline model for computing the explained individual variance
(σ2) in head circumference growth accounted for by folate treatment d Model 1 was used as baseline model for
computing the explained intercept variance (τ00) in head circumference growth accounted for by folate treatment.
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Table 4.4. Maternal and fetal characteristics of the study sample by mean head circumference
at birth (N = 215)
Variables
Mean (SD)
p-value
Overall
33.8 (2.0)
Treatment
0.1519
High-dose
34.0 (1.5)
Low-dose
33.6 (2.3)
Maternal Age
0.9197
18–24
33.7 (1.7)
25–34
33.7 (2.1)
≥35
33.9 (2.2)
Maternal Race
0.3983
Non-Hispanic white
34.0 (1.6)
Non-Hispanic black
33.5 (1.9)
Other
33.6 (3.0)
Marital status
0.0500
Married
34.5 (1.7)
Unmarried
33.7 (2.0)
Insurance Type
0.2550
Private
34.2 (1.2)
Public /Uninsured
33.7 (2.0)
Trimester
0.9417
First
33.8 (2.2)
Second
33.9 (1.7)
Body mass index
0.0723
<25
33.4 (2.1)
25–30
33.7 (2.0)
>30
34.0 (1.8)
Cotinine group
0.0004
Low
34.4 (1.4)
Moderate
33.3 (2.3)
High
33.3 (2.1)
Depression Score
0.1187
<12
33.9 (1.9)
≥12
33.3 (2.1)
Perceived Stress Score
0.8070
Low
33.7 (1.8)
High
33.8 (2.1)
Continued on next page
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Table 4.4. (Continued)
Alcohol Use
Yes
No
Illicit Drug Use
Yes
No
Hypertension
Yes
No
Diabetes
Yes
No
Heart Disease
Yes
No
Gender of child
Female
Male

0.2156
33.9 (3.0)
33.9 (1.7)
<0.0001
33.0 (2.2)
34.3 (1.5)
0.1254
33.6 (1.7)
33.9 (2.0)
0.3835
33.7 (2.1)
33.8 (1.8)
0.5576
33.4 (2.3)
33.8 (1.8)
0.2066
33.7 (1.6)
34.1 (2.1)

Trimester=trimester at study enrollment and data collection; Cotinine group=cotinine trajectory group.
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Table 4.5. Effect of folate treatment on fetal head circumference (cm) at birth (n=215)
Variables
β
SE
p-value
Intercept
34.29
0.48
<0.0001
Treatment
0.3447
High dose
0.34
0.26
0.1844
Low dose
ref
Cotinine group
Low
ref
Moderate
-1.16
0.29
<0.0001
High
-1.31
0.36
0.0004
Race
White
ref
Black
-0.72
0.29
0.0132
Other
-0.51
0.40
0.2038
*Adjusted for cotinine group trajectory and race. β= Estimate; SE= Standard error; ref= Reference group.
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Table 4.6. Maternal and fetal characteristics of the study sample by brain weight and brainbody ratio (n = 215)
Brain Weight
Brain-Body Ratio
Variables
Mean (SD)
p-value
Mean (SD)
p-value
Overall
316.1 (44.4)
10.4 (1.2)
Treatment
0.2167
0.0043
High dose
320.0 (36.4)
10.3 (1.1)
Low dose
312.5 (50.8)
10.6 (1.3)
Maternal Age
0.8748
18–24
314.9 (37.5)
10.2 (1.2)
0.1287
25–34
316.0 (47.3)
10.5 (1.2)
≥35
320.1 (51.8)
10.8 (1.4)
Maternal Race
0.3265
0.1844
Non-Hispanic white 320.6 (38.0)
10.3 (1.3)
Non-Hispanic black 310.8 (42.8)
10.6 (1.2)
Other
315.6 (64.7)
10.5 (1.2)
Marital status
0.0396
0.1580
Married
334.1 (41.5)
10.2 (0.9)
Unmarried
314.0 (44.4)
10.5 (1.3)
Insurance Type
0.4729
0.3365
Private
324.1 (30.3)
10.7 (1.2)
Public /Uninsured
315.5 (45.3)
10.4 (1.2)
Trimester
0.9450
0.4609
First
316.3 (47.4)
10.5 (1.2)
Second
315.9 (41.2)
10.4 (1.3)
Body mass index
0.0613
0.0718
<25
307.1 (44.8)
10.7 (1.3)
25–30
315.7 (45.2)
10.3 (1.2)
>30
323.9 (42.9)
10.3 (1.2)
Cotinine group
0.0004
0.0030
Low
329.5 (35.0)
10.2 (1.2)
Moderate
306.0 (50.2)
10.4 (1.2)
High
305.0 (44.4)
11.0 (1.2)
Depression Score
0.1091
0.0863
<12
318.4 (43.9)
10.4 (1.2)
≥12
305.6 (45.8)
10.7 (1.4)
Perceived Stress Score
0.7081
0.0725
Low
315.0 (41.1)
10.3 (1.2)
High
317.2 (47.5)
10.6 (1.2)
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Table 4.6. (Continued)
Alcohol Use
Yes
No
Illicit Drug Use
Yes
No
Hypertension
Yes
No
Diabetes
Yes
No
Heart Disease
Yes
No
Gender of child
Female
Male

0.2348
298.4 (66.0)
319.9 (40.3)

0.4266
10.3 (1.2)
10.6 (1.4)

<0.0001
299.5 (47.4)
327.1 (37.8)

0.3410
10.3 (1.1)
10.5 (1.4)

0.1038
324.0 (44.5)
313.0 (41.9)

0.0851
10.2 (1.2)
10.6 (1.1)

0.3830
321.3 (39.0)
315.6 (43.7)

0.2398
10.3 (1.2)
10.5 (1.2)

0.6253
313.0 (50.8)
317.5 (42.2)

0.3607
10.3 (1.2)
10.5 (1.3)

0.1300
313.9 (38.7)
323.4 (48.1)

0.6333
10.3 (1.2)
10.4 (1.2)

Trimester=Trimester at study enrollment and data collection; Cotinine group=cotinine trajectory group
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Table 4.7. Effect of folate treatment on fetal brain weight (g) at birth (n=215)
Variables
β
SE
Intercept

328.55

10.74

Treatment

p-value
<0.0001
0.2396

High dose

6.90

5.85

Standard dose

ref

-

Low

ref

-

Moderate

-25.81

6.54

<0.001

High

-29.56

8.20

0.0004

White

ref

-

Black

-16.16

6.48

0.0134

Other

-8.79

9.00

0.3296

-

Cotinine group

Race

*Adjusted for race and cotinine group trajectory. β= Estimate; SE= Standard error; ref= Reference group.

92

Table 4.8. Effect of folate treatment on fetal brain-body ratios at birth (n=215)
Variables

β

SE

p-value

Intercept

10.44

0.30

<0.0001

Treatment

0.0436

High dose

-0.33

0.16

Low dose

ref

-

Low

ref

-

Moderate

0.21

0.18

0.2506

High

0.94

0.23

<0.0001

White

ref

-

Black

0.49

0.18

0.0075

Other

0.30

0.25

0.2319

-

Cotinine group

Race

*Adjusted for race and cotinine group trajectory. β= Estimate; SE= Standard error; ref= Reference group.
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CHAPTER FIVE:

CONCLUSIONS AND RECOMMENDATIONS
This research has two main sections: (1) the cross-sectional study; and (2) the
randomized clinical trial. The findings of the cross-sectional study suggest that smokers may
have a slightly lower but insignificant red blood cell (RBC) folate than non-smokers and that a
negative correlation exists between salivary cotinine levels and RBC folate concentrations. In
the RCT conducted among smokers in pregnancy, we found that 4mg/day dose of higherstrength folic acid in combination with enrollment in a smoking cessation program had a
significant effect on birth weight, brain-body-ratio (BBR) and a trend towards significance for
the risk of small-for-gestational-age (SGA). However, higher-strength folic acid demonstrated
no effects on the rate of intrauterine brain growth, and head circumference and brain weight at
birth. A consistent finding across fetal body size outcomes was the dose-response effect of
cotinine trajectory groups. Of importance is that only 3% of the study population quit smoking
by the end of the trial, despite being enrolled in smoking cessation program and committing to
quit smoking.
The statistically significant inverse relationship between salivary cotinine levels and RBC
folate concentrations may provide evidence in support of impaired folate metabolism among
smokers and the need to increase folate supplementation among this high-risk group. The
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observed significant effect of high dose folate on birthweight, brain-to-body ratios, and a
modest protective effect on SGA are of clinical and public health relevance. These indices are
known to be connected to poor short-term and long-term health outcomes, and infant
mortality. Thus, a 140g increase in birthweight, a 0.33%-point reduction in impaired BBR and a
31% decrease in the incidence of SGA birth, as observed in this trial, would translate into lower
infant morbidity and mortality, and a reduction in health care expenditures. Infants with SGA
and higher BBBR are more likely to have neurocognitive problems.123 A reduction in SGA births
and children with impaired BBR could considerably impact the number of individuals who
would require services such as special educational resources and social support due to
neurocognitive and behavioral problems.
Smoking cessation is a well-established, effective preventive measure to improve birth
outcomes but it is not particularly useful in low-income mothers as observed in this trial. Thus,
there is a need to investigate smoking interventions that are tailored and developed specifically
for this sub-group and identify ways to improve birth outcomes for smokers in pregnancy.
Higher-strength folic acid supplementation seems like an effective, safe and cheap option.
Practically, the health care provider may be able to prescribe this affordable supplement to atrisk low-income mothers and increase their likelihood of having infants with higher birth weight
and appropriate-for-gestational-age babies. Infants born to mothers with lower levels of
cotinine had a reduced risk of adverse fetal brain and body size outcome than those born to
mothers with higher levels of cotinine. Getting women to reduce smoking or maintain minimal
smoking, if they cannot completely quit, will have significant implications for decreasing the
incidence of adverse birth outcomes and future health problems. Being able to increase birth
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weight and reduce SGA births in these disadvantaged group of women may contribute
significantly to decreasing infant health disparities in the United States. This aligns with the
Healthy People 2020 goals of reducing the rate of fetal and infant deaths [(Maternal, Infant and
Child Health, Objective 1 (MICH-1)].124

Further Research Needed
Higher strength folic acid supplementation may have the potential to offer smokers in
pregnancy a safe, comfortable and convenient option to reduce their risk of adverse birth
outcomes. Additionally, the possibility of a decrease in SGA births by approximately 31% would
be huge considering the number of cases of SGA births that can be prevented, and the
subsequent reduction of burden on families and the health care system. Higher strength folic
acid supplementation in pregnant women who smoke might be a cost-effective way to reduce
low birth weight and SGA associated infant morbidity and mortality. Future studies with larger
sample sizes and diverse populations are indicated to confirm or refute the results of this study.
Of importance are those results that showed a trend towards statistical significance; they are
worthy of further investigation to determine true associations. Additionally, future research
should investigate the effect of potential modifiers, such as cotinine trajectory group on the
association between higher strength folate supplementation and birth outcomes. Observational
studies have demonstrated a significant reduction in SGA risk, only if folic acid supplementation
is commenced before conception. Randomized controlled trials with startup during the
preconception period and follow-up until delivery are warranted to identify the most folatesensitive period of fetal growth. These studies should aim to determine the optimal dose of
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folic acid supplement, and compare the effects of folate assessed via biomarker test vs. selfreported supplementation on birth outcomes.
In conclusion, the findings from this study contribute to the body of evidence regarding
the effect of maternal folic acid supplementation on fetal brain and body size among lowincome mothers who smoke during pregnancy. It is the first RCT to investigate the efficacy of
folic acid in improving adverse birth outcomes among smokers. The folate-dependent pathway
is one of the many plausible mechanisms that link tobacco use in pregnancy to adverse birth
outcomes. We hope that this study will stimulate further multi-pathway research in mitigating
the effects of prenatal smoking on adverse birth outcomes.
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APPENDIX 1. REVIEW OF THE LITERATURE

A1.1. PERINATAL SMOKING
Harmful health behavior such as smoking is prevalent during the periconceptional
period among women. About 21% of women of reproductive age smoke and approximately 1014% of women continue to smoke during pregnancy1-4 in spite of substantial evidence of its
deleterious health effects. Not only is the rate of smoking high among women, about one-third
of women of reproductive age are also exposed to environmental tobacco smoke i.e. secondhand exposure.5
Smoking during pregnancy remains one of the most preventable and highly prevalent
causes of infant morbidity and mortality. In the United States, it accounts for over 1000
perinatal deaths each year6 and is a significant cause of a range of adverse pregnancy outcomes
including intrauterine growth restriction, miscarriage, preterm birth, Sudden Infant Death
Syndrome (SIDS) and placental abruption.7-9 Prenatal smoking is also associated with long-term
consequences of neurodevelopment disorders and impaired cognitive function in the
offspring,10 attention deficit disorders,11,12 behavioral problems, 13,14 and antisocial
behavior.15,16
Public health initiatives have helped reduce the prevalence of smoking in pregnancy
over the past few decades, but disparities still exist with lower rates of decline among women
of lower socioeconomic status.9 Women who continue to smoke during pregnancy usually have
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a low income, limited education, high parity, are without a partner, have low levels of social
support, and receive publicly funded maternity care.9,17-19

A1.2. FOLATE
Folate or vitamin B9 is one of the 13 essential vitamins. It cannot be synthesized de
novo by the body and must be obtained either from food intake or dietary supplementation.20
Dietary folate is a naturally occurring nutrient which can be consumed through food sources
such as leafy green vegetables, egg yolk, liver, legumes, and citrus fruit. The synthetic dietary
supplement form of folate that is present in artificially enriched foods and pharmaceutical
vitamins is called folic acid. Folic acid (pteroylglutamic acid) is used to denote the fully oxidized
chemical compound, not present in natural foods while ‘folate’ is a more encompassing term
that is used to indicate the large group of compounds possessing the same vitamin activity.21
Adequate folate intake, particularly in pregnancy is required for cell division and
homeostasis due to the vital role of folate coenzymes in nucleic acid synthesis, methionine
regeneration, and in the oxidation, and reduction of one-carbon units required for normal
metabolism.22 The supply of folate coenzymes in the body depends primarily on the quantity
and bioavailability of ingested folate and the rate of excretion in the urine and feces through
catabolism. In pregnancy, the demands for folate increase because it is required for fetal
growth and development.20,23 Folate deficiency has been associated with health problems in
mothers (such as anemia, peripheral neuropathy) and their babies (such as preterm birth and
congenital abnormalities).20
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Several studies including a recent systematic review of randomized or quasi-randomized
trials evaluating the effect of periconceptional folate supplementation in preventing neural
tube defects24-28 showed a protective effect of daily folic acid supplementation (alone or in
combination with other vitamins and minerals) on neural tube defect (NTDs). Based on the
consistent evidence about the protective effect of folic acid supplementation against NTDs, the
United States Public Health Service recommended daily supplementation with 400μg (0.4mg) of
folic acid for all women of reproductive age.29 Despite the known advantages of folate, many
women still do not follow the recommendations, and this is particularly true for women from
low socioeconomic backgrounds.30,31 Additionally, study on trends in red blood cell (RBC) folate
demonstrates disparity by race.32 Certain race groups including non-Hispanic black women are
yet to meet the 2010 national health objective of increasing the median RBC folate level among
women of reproductive age to 220 ng/mL RBC.32

A1.3. SMOKING AND FOLATE
The negative association between smoking, and folic acid intake and metabolism is well
documented in the literature.33-36 Smokers are less likely to consume quality diet including
adequate folate37and have increased oxidative catabolism and altered absorption of serum
folate.38 Research has shown that smokers have lower serum folate levels than nonsmokers.3941

Tobacco smoke exposures in pregnancy may increase disease risk among children by

reducing folate bioavailability during the critical period of fetal development. 36, 42-45
Since there is evidence to support lower serum folate among smokers, folic acid
supplementation during pregnancy may be relevant to smokers and in higher dose than in non111

smokers. This is because of its importance in DNA synthesis and repair from damages due to
smoking coupled with increased folate demand in pregnancy.33,46,47 The process of DNA
methylation is dependent on the presence of methyl donors (provided by nutrients such as folic
acid, methionine, and choline) and methyltransferases. As folate is an important substrate in
methylation reactions, the demand for folate may be higher in smokers than in non-smokers,
thereby depleting folate stores. Because of the depleting folate stores during pregnancy, there
is a decline in the major methyl donor, S-adenosyl methionine (SAM) which is required for DNA
methylation48; a process required for optimal fetal growth.49, 50

A1.4. PRENATAL SMOKING AND FETAL BODY AND BRAIN SIZE
Maternal smoking can cause several adverse health outcomes across the lifespan.
However, in comparison to adults, the developing fetus may be particularly sensitive to the
harmful effects of smoking because of reduced nicotine detoxification capability.51, 52 Birth
weight is the most important predictor of infant health and survival. The effect of prenatal
smoking on increased risk of low birth weight (LBW) and intrauterine growth restriction is well
documented.53-57 Tobacco exposure during pregnancy is associated with impaired fetal growth
from early pregnancy onwards and increases the risks of neonatal and future health
complications.55,58,59
Numerous studies have also observed reduced fetal head circumference and biparietal
diameter in fetuses of smoking mothers and have described these parameters of general
symmetrical intrauterine growth restriction.55,60-63 Jaddoe et al55 found that continued maternal
smoking in pregnancy led to a reduction in the growth of head circumference by about 0.56
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mm/week, and the degree of growth restriction was found to be dose-dependent on smoking
levels. Unlike in animal studies where nicotine has been shown to directly inﬂuence fetal brain
development (the use of animal models permits a direct assessment of causality),64 an indirect
pathway has been suggested in humans. This evidence is based on studies that indicate that the
relationship between perinatal smoking and behavioral/cognitive development in the offspring
may be mediated by brain deﬁcits or reduced fetal head size.65

A1.5. FOLIC ACID AND FETAL BODY AND BRAIN SIZE
During pregnancy, folate requirements are 5- to 10-fold higher than in non-pregnant
women to cover the needs of fetal growth and development.66 Low folate intake and low RBC
folate level in the late pregnancy increase the risk of SGA birth.40,67,68 Several studies suggest a
possible benefit of maternal folate consumption or high serum/RBC folate level on birth weight.
40,67-70

In a review of randomized clinical trials (RCTs) investigating the effect of folic acid

supplementation on birth weight, a significant dose-response association between folate intake
and birth weight was observed.70
The role of folate in brain growth has also been established, and the changes in brain
structure due to folate deficiency may be long-lasting and contribute to behavioral difficulties
later in life.71 Conversely, high total folate intake and maternal erythrocytes folate
concentration in early pregnancy promote growth in the fetal head.72 Results from the Schlotz
et al72 longitudinal study of a birth cohort also show inverse associations between maternal
folate status in early pregnancy with behavioral problems (hyperactivity/inattention and peer
problems) in childhood. These associations were found to be mediated by fetal head
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circumference at birth. Head circumference correlates closely with fetal brain volume73 and is
used as a proxy for assessing brain growth.74
Some biologically plausible hypotheses have been used to explain the associations
between maternal folate status and fetal size such as a reduction in concentration and activity
of maternal folic, and reduced placental blood flow (Figure A1.1) Folate has many roles in cell
function and gene expression, through the process of DNA methylation.75 Low folate level is
associated with elevated total homocysteine (tHcy). The high serum levels of this amino acid
have been associated with several clinical conditions, including placental vasculopathy,76,77
which is well known to affect fetal growth.78 Fetal growth may be influenced directly by
elevated tHcy or through other effects of reduced folate such as modulation of gene expression
through altered DNA methylation.79
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Figure A1.1. Pathways through which smoking could lead to adverse birth outcomes
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APPENDIX 2. SUPPLEMENT TABLES AND FIGURES
Table A2.1. Baseline characteristics of the study sample by mean blood folate concentrations
Variables
Erythrocyte Folate, ng/mL
Overall
Maternal Age
18–24
25–34
≥35
Maternal Race
Non-Hispanic white
Non-Hispanic black
Other
Marital status
Married
Unmarried
Insurance Type
Private
Public /Uninsured
Trimester at enrollment
First
Second
Body mass index
<25
25–30
>30
Depression Score
<12
≥12
Perceived Stress Score
Low
High
Smoke Tobacco
Yes
No

Median (25th, 75th percentile)
718.0 (577.0, 860.0)

P-value
0.384

704.0 (569.0, 835.0)
718.0 (579.0, 853.0)
763.0 (542.0, 917.0)
0.613
730.0 (580.0, 874.0)
705.0 (567.0, 842.0)
727.0 (579.0, 838.0)
0.939
712.0 (585.0, 876.0)
716.5 (571.5, 858.0)
0.632
711.0 (583.0, 811.0)
716.0 (573.0, 865.0)
<0.001
655.5 (533.0, 801.0)
788.0 (654.0, 935.0)
0.023
690.5 (558.5, 801.5)
697.5 (579.0, 855.0)
752.0 (582.0, 895.0)
0.386
712.0 (569.0, 851.0)
724.0 (580.0, 910.0)
0.262
706.0 (560.0,864.0)
741.0 (592.0, 857.0)
0.835
716.5 (577.5, 859.5)
712.0 (567.0, 865.0)
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Table A2.2. Spearman correlation coefficients for folate level and continuous covariates
Spearman Correlation Coefficients
Prob > |r| under H0: Rho=0
Number of Observations
Folate
Folate Level

1.00000

Age

GA in weeks EPDS

PSS

0.06558

0.27895

0.04066

0.03075

0.1451

<.0001

0.3681

0.4971

495

495

495

492

490

Maternal Age

0.06558

1.00000

0.07127

0.00084

-0.03127

Age

0.1451

0.1129

0.9851

0.4894

Folate

495

496

496

493

491

Gestational Age

0.27895

0.07127

1.00000

0.01334

0.00252

GA in weeks

<.0001

0.1129

0.7676

0.9556

495

496

496

493

491

Depression Score

0.04066

0.00084

0.01334

1.00000

0.66402

EPDS

0.3681

0.9851

0.7676

492

493

493

493

488

Stress Score

0.03075

-0.03127

0.00252

0.66402

1.00000

PSS

0.4971

0.4894

0.9556

<.0001

490

491

491

488
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<.0001

Table A2.3. Spearman correlation coefficients for cotinine level and continuous covariates
Spearman Correlation Coefficients
Prob > |r| under H0: Rho=0
Number of Observations
Cotinine
Cotinine

1.00000

Maternal Age

GA in weeks

EPDS

PSS

0.06639

0.08681

0.28958

0.26297

0.1402

0.0536

<.0001

<.0001

495

495

495

492

490

Maternal Age

0.06639

1.00000

0.07127

0.00084

-0.03127

Age

0.1402

0.1129

0.9851

0.4894

Cotinine

495

496

496

493

491

Gestational age

0.08681

0.07127

1.00000

0.01334

0.00252

GA in weeks

0.0536

0.1129

0.7676

0.9556

495

496

496

493

491

Depression Score

0.28958

0.00084

0.01334

1.00000

0.66402

EPDS

<.0001

0.9851

0.7676

492

493

493

493

488

Stress Score

0.26297

-0.03127

0.00252

0.66402

1.00000

PSS

<.0001

0.4894

0.9556

<.0001

490

491

491

488
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<.0001

491

Table A2.4. Schedule of data collection, instruments and procedures used in the in the study
Baseline
Visit 1
Visit 2
Delivery
Visit
Gestational Age (GA)

American College of

<21 weeks

18-27

28-36

GA at

weeks

weeks

Delivery

X

X

X

X

Obstetrics and Gynecology form (ACOG)
Edinburgh Perinatal

X

Depression Scale (EPDS)
Perceived Stress Scale 14 (PSS-14)

X

Salivary Cotinine

X

Red Blood Cell Folate

X

Fetal Body Measures
Fetal Ultrasound Brain Measures

X
X

X
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X

Table A2.5 Cotinine group-based trajectory model comparisons
Number of

Number of

All Linear Terms

All Quadratic Terms

Latent

groups in the

BIC

BIC

Subgroups

Null Model

2

2(∆BIC)

-1766.9

2(∆BIC)

-1769.6

3

2

-1745.8

42.2

-1741.6

56.0

4

3

-1743.6

4.4

-1739.7

3.8

5

4

-1752.3

-17.4

-1751.23

-23.0

6

5

-1760.9

-17.2

-1740.5

21.4

2(∆BIC) = log Bayes factor approximation.
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Table A2.6. Determining the best polynomial degree for each trajectory in a three-group
model using BIC

Model

Polynomial degree

BIC

1

121

-1736.0

2

122

-1738.8

-2.8

3

221

-1738.8

-2.8

4

222

-1741.6

-5.6

5

111

-1745.8

-9.8

6

112

-1748

-12

7

211

-1748.7

-12.7

8

212

-1750.9

-14.9

2(∆BIC) = log Bayes factor approximation.
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2*(∆BIC)

Table A2.7. Cotinine group-based trajectory model comparisons
Number of

Number of

All Linear Terms

All Quadratic Terms

Latent

groups in the

BIC

BIC

Subgroups

Null Model

2

2(∆BIC)

-1766.9

2(∆BIC)

-1769.6

3

2

-1745.8

42.2

-1741.6

56.0

4

3

-1743.6

4.4

-1739.7

3.8

5

4

-1752.3

-17.4

-1751.23

-23.0

6

5

-1760.9

-17.2

-1740.5

21.4

2(∆BIC) = log Bayes factor approximation.
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Table A2.8. Determining the best polynomial degree for each trajectory in a three-group
model using BIC

Model

Polynomial degree

BIC

1

121

-1736.0

2

122

-1738.8

-2.8

3

221

-1738.8

-2.8

4

222

-1741.6

-5.6

5

111

-1745.8

-9.8

6

112

-1748

-12

7

211

-1748.7

-12.7

8

212

-1750.9

-14.9

2(∆BIC) = log Bayes factor approximation.
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2*(∆BIC)

Table A2.9. Model comparisons for estimation method
Covariance
Model

-2RLL

AIC
Parameter

Compound Symmetry

8232.1

8238.1

3

Unstructured

8144.0

8152.0

4

Autoregressive

8232.1

8232.1

3

Autoregressive Heterogenous Variances 8144.0

8152.0

4

Variance Components

8214.5

3

8197.9

*p<.001. Models with lower -2LL
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Table A2.10. Basic statistical measures on location and variability of outcomes
Mean

Median

Mode

SD

Variance

HC at birth

33.8

34.0

34.0

1.9

3.9

Brain Weight

10.4

10.4

9.5

1.2

1.5

BBR

316.1

319.2

319.2

44.4

1972.0
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Table A2.11. Spearman correlation coefficients for fetal brain outcomes and other continuous
covariates
Spearman Correlation Coefficients
Prob > |r| under H0: Rho=0
Number of Observations
Head
Brain
Circumference Weight
Head
Circumference

Brain
Weight

Brain-Body
Ratio

Gestational
Age

Birthweight

Age

1.00000

BrainBody
Ratio

Gestational Birth
Age
Weight

Age

1.00000

-0.01923

0.31719

0.69642

0.00734

<.0001

0.7792

<.0001

<.0001

0.9148

215

215

215

215

215

215

1.00000

1.00000

-0.01923

0.31719

0.69642

0.00734

0.7792

<.0001

<.0001

0.9148

<.0001
215

215

215

215

215

215

-0.01923

-0.01923

1.00000

-0.27356

-0.67971

0.17881

0.7792

0.7792

<.0001

<.0001

0.0086

215

215

215

215

215

215

0.31719

0.31719

-0.27356

1.00000

0.39817

-0.14460

<.0001

<.0001

<.0001

<.0001

0.0345

215

215

215

215

215

215

0.69642

0.69642

-0.67971

0.39817

1.00000

-0.11564

<.0001

<.0001

<.0001

<.0001

215

215

215

215

215

215

0.00734

0.00734

0.17881

-0.14460

-0.11564

1.00000

0.9148

0.9148

0.0086

0.0345

0.0915

215

215

215

215

215
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0.0915

215

Figure A2.1. Histogram and probability plot of birth weight
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Figure A2.2. Histogram and probability plot of head circumference at birth
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Figure A2.3. Histogram and probability plot of fetal brain weight
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Figure A2.4. Histogram and probability plot of fetal body-brain ratios
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Head circumference (mm)

Gestational age in weeks (centered)

Figure A2.5. Spaghetti plot of the trajectories in head circumference of fetuses of all
participants on high dose folate in the study
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Head circumference (mm)

Gestational age in weeks (centered)

Figure A2.6. Spaghetti plot of the trajectories in head circumference of fetuses of all
participants on standard dose folate in the study
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